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ABSTRACT 
Invasive pneumococcal disease (IPD), which includes potentially fatal conditions such as 
meningitis, septicaemia and pneumonia poses a threat in children aged <5 years, pneumonia 
being the leading cause of child mortality worldwide. Even though capsular polysaccharides are 
the main antigens involved in the immunity to encapsulated bacteria, it was found that in 
children in that age group, the immune system was unresponsive. Conjugate vaccines however 
induce immunologic memory and provide long-term protective immunity. Therefore the aim of 
this project was to develop novel conjugation strategies towards a pneumococcal conjugate 
vaccines and focuses mainly on the serotypes that are a burden to the African continent.  
The chemistry involved in developing a conjugate vaccine is of importance beacuse while some 
polysaccharides contain chemical grouping which can be conveniently utilized for conjugation, 
many medically important ones require derivatization before they can be coupled to protein. 
Derivatization of which can be achieved through various strategies, important to note is through 
hypervalent iodine oxidants. 
Two hypervalent iodine reagents, O-Methyl substituted-1-hydroxy-1,2-benziodoxol-3(1H)-one 
1-oxide (Me-IBX)and modified 1-hydroxy-1,2-benziodoxol-3(1H)-one 1-oxide (mIBX)were 
successfully synthesized in preparation for the use in polysaccharide, polyribitol phosphate, 
(PRP) oxidation. The polysaccharide to be oxidised was first size reduced by microfluidisation to 
allow maximum oxidation. However, the extent to which oxidisation was achieved was not 
enough to conjugate the polysaccharide to the protein of preference, Bovine Serum Albumin, 
(BSA).   
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CHAPTER 1 
INTRODUCTION 
1.1  Background to Streptococcus pneumonia 
Human infections caused by Gram-positive bacterial pathogens are increasingly difficult to treat, 
predominantly due to the emergence of antibiotic-resistant strains against penicillin and 
penicillin-like antibiotics.
1
 One such Gram-positive bacterial organism is Streptococcus 
pneumonia which is a catalase-negative facultatively anaerobic organism that grows most often 
as “lancet shaped” diplococci, but may also grow as a single coccus or in short chains. On blood 
agar, colonies are a hemolytic, surrounded by green or brown discoloration of the medium, 
which is caused by partial lysis of red blood cells as seen in Fig 1.
2
  
 
Figure 1 Streptococcus pnuemonia on blood agar
3
 
Through a combination of virulence factor activity and an ability to evade the early components 
of the host immune response, this organism can spread from the upper respiratory tract to the 
sterile regions of the lower respiratory tract which leads to pneumonia.
4 
In addition to causing 
disease primarily confined to the mucosal surface of the respiratory tract, the pneumococcus 
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commonly causes bacteremia and infections that result from dissemination via the bloodstream. 
Characteristics of the bacteria that allow it to colonize the mucosal surface of the nasopharynx 
and to survive within the blood stream are not completely understood.
5
 The pneumococcal outer 
surface comprises three main parts, namely: the cell membrane, the cell wall and the capsule, Fig 
2. 
 
Figure 2 Structure of Streptococcus pneumoniae
6
 
Polysaccharide capsules are ubiquitous structures found on the cell surface of a broad range of 
bacterial species. The polysaccharide capsule often constitutes the outermost layer of the cell and 
as such, it may mediate direct interactions between the bacterium and its immediate environment 
and has been implicated as an important factor in the virulence of many animal and plant 
pathogens. Fig 3 illustrates what the capsule is comprised of.
7
 Important to note in Fig. 3 are the 
extracellular components of the bacterial cell. Capsular polysaccharide (CPS) is found on the 
outer layer, bound firmly to the cell wall polysaccharide (CWPS) via peptidoglycan linkages. 
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Figure 3 Structure of capsular polysaccharide
8
 
 
1.2 The Structure of the Capsular Polysaccharide (CPS) 
The bacterial capsule is vital for survival of the bacterium in the blood and is strongly linked 
with the capability pneumococcus has to cause invasive disease. The capsular exterior is 
exposed, and therefore antibodies against capsular polysaccharide provide a defense against 
pneumococcal disease.2 More than ninety different immunologically distinct capsular 
polysaccharides have been identified with distinct serological patterns and chemical structures,
9
 
and they are either numbered in the order in which they were identified (American system) or are 
grouped by antigenic similarities (Danish system); the latter is more widely accepted. There is 
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widespread cross-reactivity among particular polysaccharides within the 90+ serologically 
different pneumococcal capsular polysaccharides. This cross-reactivity was established by 
categorizing serologically related polysaccharides into groups. After pneumococcal infection, 
type-specific protective antibodies against the capsular polysaccharide are formed. The 
immunologic and chemical specificity of the polysaccharide capsule is the basis for development 
of a pneumococcal vaccine.2  
Not all 90+ serotypes are equally pathogenic and they differ in their structures. Looking at 
structures of some of the serotypes present in one of the licensed vaccines viz., PCV 13, their 
individuality is evident. Table 1 illustrates the polysaccharides in a few of the serotypes. 
Table 1 Serotypes and their structures 
Serotype Structure 
4 →3-β-ManNAc-(1→3)-α-L-FucNAc-(1→3)-α-D-GalNAc-α-D-Galp-(1→ 
 
6B →2-α-D-Galp-(1→3)-α-D-Glcp-(1→3)-α-L-Rhap-(1→4)-D-Ribitol-5-P-(O- 
 
6A →2-α-D-Galp-(1→3)-α-D-Glcp-(1→3)-α-L-Rhap-(1→3)-D-Ribitol-5-P-(O- 
 
14 
 
18C 
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6A and 6B, Table 1 account for 14% - 18% of IPD across the different regions of the world.
10
 
Because of their medical importance, the molecular natures of serotype 6A and its related 
serotype, serotype 6B, have been studied extensively. Biochemical studies found that the 
capsular polysaccharides (PSs) of serotypes 6A and 6B are linear polymers with a repeating unit 
containing four monosaccharides/ alditols viz., rhamnose, ribitol-phosphate (P), galactose, and 
glucose.9 The two PSs are identical except for a difference in the linkage between rhamnose and 
ribitol (Fig 4 illustrates the structural differences). Group 6 consists of the pneumococcal 
capsular polysaccharides, 6A, 6B, 6C that were identified in 2007 on the basis of their  distinct 
binding patterns with two monoclonal antibodies
11,12,13
 and 6D created by mutating the critical 
nucleotide in the wciP gene of the 6C capsule gene locus or by inserting the wciNβ gene into the 
6B capsule gene locus.13 The natural existence of serotype came to be known recently when two 
studies found its strains in nasopharyngeal aspirates from children in Fiji during 2004 - 2007
14
 
and in 2 nasopharyngeal aspirates from children in South Korea in 2008.
15
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Figure 4 Chemical structures of Pn 6A and Pn 6B8 
  
1.3 Epidemiology  
Streptococcus pneumoniae is responsible for 70-80% of severe pneumonia cases in the African 
continent.
16,17
 Most of these deaths occurred in poor countries and included a disproportionate 
number of children under the age of 2 years.
8,15,17
 Although all age groups may be affected, the 
highest rate of pneumococcal disease occurs in young children and in the elderly adults. In 
addition, persons suffering from a wide range of chronic conditions and immune deficiencies are 
at increased risk.
18
 Fig. 5 illustrates that from all the diseases causing child mortality, pneumonia 
dominates with a percentage of 29 % and thus there is an urgent need to develop effective 
Pneumococcal Conjugate Vaccines (PCV).  
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Figure 5 Diseases causing children’s deaths19 
 
Since there are 90+ distinct capsular types, as mentioned above, it has been ascertained that most 
cases of pneumococcal pneumonia appear to be caused by a subset of 23 types which constitute 
the basis of the 23-valent vaccine, PneumoVax23, currently used in several countries.
20
 
Vaccines that protect against the disease S. pneumonia and other diseases such as meningitis and 
Haemophilus influenza type b, such as the 23-valent polysaccharide vaccine, were also thought 
to have a theoretical coverage of over 80 % of pneumococcal diseases, currently available on the 
market and are specifically based on the polysaccharide capsule of the bacteria. However, these 
vaccines containing the polysaccharide only, produce weak responses in infants and young 
children and in older age groups, since it only offers a short term immune response.
9 
The poor 
immune response to the polysaccharide antigen in this age group is due to the lack of T-cell 
dependent immune response which is a requirement for high-level antibody response and 
induction of immunological memory B cells which limits the period of protection of this vaccine. 
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The polysaccharide vaccine is also not effective against the common acute otitis media caused by 
S. pneumoniae. Conjugate vaccines in which the polysaccharide is attached to an immunogenic 
carrier protein are able to induce T-cell dependent immune responses even in infants,
20,18,21  
thus 
providing humoral, long term, memory.   
In 2000, a 7-valent pneumococcal conjugate vaccine (PCV7, Prevnar®) was licensed in the 
United States that contains capsular polysaccharides corresponding to serotypes 4, 6B, 9V, 14, 
18C, 19F and 23F conjugated to the carrier protein CRM197, a nontoxic variant of diphtheria 
toxin, thereby providing coverage for the seven most prevalent serotypes causing IPD in infants 
and children in the United States at the time.
22,23
 In 2010, a 13-valent pneumococcal conjugate 
vaccine (PCV13, Prevnar 13™) was licensed in the United States that expanded the serotype 
coverage to additionally include serotypes 1, 3, 5, 6A, 7F and 19A. PCV13 is expected to 
provide protection for the 13 most prevalent serotypes causing pneumococcal disease in infants 
and children globally.
24,25,26,27
 
As seen in Fig 6, incident rates of IPDs dropped dramatically in the under 5 years target group 
after the introduction of the vaccine in America. The efficacy of the vaccine in the United States 
as well as Europe was 97 % in preventing vaccine-serotype-specific IPD. The number of IPD 
cases in children below 5 years of age had fallen from an average of 17 240 cases per year before 
the introduction of conjugate vaccines to 4 454 cases in 2003. 
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Figure 6 Rate of vaccine-type IPD in United States before and after introduction of PCV7, by age group 
and year
28
. 
Although the serotypes included in PCV-7 were estimated to cover 80-90 % of serotypes causing 
IPD in young children in North America and Australia, this number decreased to 70 – 75 % in 
Western Europe and Africa and to only 50-65 % in Latin America and Asia as seen in Fig 7. 
Serotypes not found in PCV-7 appeared to play an important role in certain disease syndromes 
and in some age groups. Serotypes 1, 5, and 7F in particular had been associated with severe 
clinical syndromes and the risk of severe disease and death due to pneumococcal infection was 
found to be the highest following serotype 7F infection. Serotype 1 was implicated in 
complicated pneumonia and pleural empyema in children and is commonly isolated in children 
over 2 years of age, and is an important cause of IPD in Asia and Africa. Serotype 5 was the 
third most important serotype causing IPD in young children in Latin America
29
  
 
 
 
 
  
32 
 
Figure 7 Proportion of IPDs in children under 5 years of age predicted to be due to serotypes included in 
the 7-10 and 13 valent formulations.
19
 
 
1.4 Geographical variation 
In children with invasive pneumococcal disease (IPD), the most widespread serotypes in the 
United States in a countrywide investigation carried out in 1978-1994 were 14, 6B, 19F, 18C, 
23F,4 and 9V. These serotypes, as well as serologically cross reacting serotypes, accounted for 
86 % of S. Pneumoniae isolates isolated from children under 6 years old with bacteria and 83 % 
of those with meningitis.2 The scattering of serotypes differs by geography,
30,31,32
 and the 
predominance of a given serotype may change with time. For example, types 1 and 5 are more 
common in parts of Europe and the developing world, but not in the United States.
33
 
The selection of serotypes in the presently existing vaccine is based mostly on those invasive 
diseases in Western Europe and North America. However, there are regional variations in 
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pneumococcal serotypes causing acute illness. For example, the 7-valent conjugate vaccine 
(PCV7), Fig 8 covers serotypes raging from about 40% of serotypes occurring in Asia to 60% in 
Latin America and Africa to 73% in Australasia and 86% in North America.
34
   
 
Figure 8 Coverage of PCV7 around the world19 
Surveillance suggests an increase in disease in children aged < 5 years due to these nonvaccine 
serotypes, especially serotypes 3, 6A, and 19A, some of which are antibiotic resistant. Because 
children are the reservoir for the serotypes that cause invasive disease in older people, 
broadening the coverage of serotypes in the vaccine is desirable. Therefore in addition to PCV7, 
a 10-valent and a 13-valent vaccine have been developed. These contain additional serotypes that 
are not present in PCV7. Fig. 9 is illustrates the serotypes that these three different multivalent 
vaccines are comprised of.  
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Figure 9 Streptococcus pneumonia vaccines19 
 
Figure 10 Serotypes causing Invasive Pneumococcal Disease in Africa19  
 
1.5 Vaccines 
Despite the large number of pneumococcal serotypes, most cases of disease are caused by 
relatively few serotypes. The serotypes in Fig 10 are mainly linked with pneumococcal illness 
and the others rarely lead to illness. Many countries have licensed vaccines based on the capsular 
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polysaccharide of these 23 serotypes since these vaccines have been demonstrated to be effective 
against IPD and for the defence of persons who are in specific danger of the disease. However, 
their addition to national infant immunizations schedules has been prevented by their incapability 
of inducing high-quality immunological memory and of eliciting protective responses in young 
infants.
35
 In addition, pneumococcal vaccination with these vaccines is about 50-80 % effective 
in preventing IPD among elderly people, and vaccine-generated defence weakens after 3-5 
years.
36
 
The development of pneumococcal vaccines has existed since the early 20’s, with a couple of 
vaccines being introduced to the public, but withdrawn due to the belief that pneumococcal  
illness could be easily cured by the use of penicillin. Even though in 1911-1913, a Sir Almroth 
Wright was able to reduce the incidence of pneumonia in mine workers by 50 % with a vaccine 
consisting of dried, heat inactivated sputum from pneumonia patients in South Africa, it wasn’t 
until 1946 that pneumococcal polysaccharide vaccines were first released in the US and were 
withdrawn shortly thereafter in the belief that as with most bacteria, pneumococcal diseases 
could be eliminated through the use of antibiotics. In 1977 a penicillin resistant strain of S. 
pneumoniae was discovered in South Africa which quickly spread worldwide. This resistant 
strain brought about the reintroduction of the pneumococcal polysaccharide in the US in 1977. 
Table 2 illustrates the resistance and sensitivity of certain antibiotics in infants. 
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Table 2 Streptococcus pneumonia antibiotic resistance and sensitivity 
Infant 
no 
Age 
(mnths
) 
Serotyp
e 
Penicillin
* (MIC) 
Contrimo
--xazole 
Erythro-
mycin 
Tetra-
cycline 
Cefachlor Chloram-
phenicol 
Lineezolid 
1 9 - ** R (0.5) R S S S S S 
4 9 23F R (0.25) R S S S S S 
8 9 - R (1) R S R S S S 
11 2 15A/15F R (0.25) R S S S S S 
12 1 6A/6B R (0.5) R S S S S S 
20 9 23F R (0.5) R S S S S S 
21 1 7C/7B R (0.5) R S S S S S 
23 2 - R (0.12) R S S S S S 
27 1.5 23A R (0.25) R S S S S S 
30 2.5 6A/6B R (0.5) R S R S S S 
31 1.2 19A R (0.25) R S R S S S 
34 3 6A/6B R (0.5) R S R S S S 
36 5 6A/6B R (0.25) R S S S S S 
31 2 19F R (0.5) R S S S S S 
Colonization 
Rate 
39 % 100 % 
Resistanc
e Rate 
100 % 
Resistanc
e Rate 
0 % 
Resistanc
e Rate 
25 % 
Resistanc
e Rate 
0 % 
Resistanc
e Rate 
0 % 
Resistanc
e Rate 
0 % 
Resistanc
e Rate 
*All isolates expressed low level penicillin resistance; the values represent minimum inhibitory concentration (MIC) for each 
isolate 
**- Isolates not been serotyped by our PCR. R = Resistant, S = sensitive 
Current S pneumoniae vaccines are based on the use of the bacterial capsular polysaccharides 
(PS), which induce type-specific antibodies that activate and fix complement and promote 
bacterial opsonization and phagocytosis. In 1977, a 14-valent pneumococcal polysaccharide 
vaccine, based on the purified capsular polysaccharide was licensed in the United States which 
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was later replaced by the currently marketed 23-valent vaccine PPV23 in 19832 as illustrated in 
Table 3.   
Table 3 Licensed pneumococcal polysaccharide vaccines (PVV)  
Vaccine Type Company name Serotypes included Licensed date 
PPV-14 Merck 1, 3, 4, 6A, 6B, 7F, 8, 9N,  12F, 14, 18C, 19F, 20, 23F 1977 
PPV-23 Merck 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 
15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F 
1983 
The pneumococcal serotypes responsible for 85 - 90 % of invasive pneumococcal infections in 
the USA and some other industrializing countries are represented by the PPV23. The two 
vaccines currently manufactured are PneumoVax 23™ by Merck and Pneumo 23™ by Sanofi 
Pasteur. The vaccine is effective against in IPD’s and pneumonia in individuals that are 
considered to be healthy, particularly among adults, however shows limited efficacy in young 
children less than 2 years of age. Because the polysaccharide based vaccines do not induce a 
protective serum antibody response in infants, pneumococcal conjugate vaccines were 
introduced.  
Pneumococcal conjugate vaccines are based on the coupling of the capsular polysaccharide from 
diverse streptococcus pneumonia serotypes to a variety of protein carriers. These polysaccharide-
protein conjugates increase the immunogenicity of a bacterial capsular polysaccharide in infants 
and elderly immunodeficient individuals.
37
 . There are several different methods of conjugation. 
However, the most successful ones have been performed by activating the hydroxyl or carboxyl 
groups on the polysaccharide and either coupling the activated polysaccharide directly to the 
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protein or first coupling the activated polysaccharide to a linker molecule, such as adipic acid 
dihydrazide (ADH), the other end of which is coupled to a linker protein. Since the chemistry 
should not alter the composition of the polysaccharide to void its immunogenicity as well as 
preventing cross linking within the polysaccharide or protein and cross reactivity between 
conjugates, it is important to carefully choose what chemistry to follow when coupling the 
polysaccharide to the protein to successfully produce a vaccine that is immunogenic. The choice 
of conjugation chemistry is dependent on the functional groups of the polysaccharide and carrier 
protein. 
Conjugates can be prepared by direct reductive amination with sodium cyanoborohydride as with 
Pfizer’s 7 and 13 valent conjugates. GSK’s licensed pneumococcal conjugate vaccine is based on 
the activation of the hydroxyl groups of the saccharide with 1-cyano-4-dimethylaminopyridium 
tetrafluoroborate (CDAP) to form a cyanate ester. The activated saccharide can then be coupled 
directly or through a spacer group to the amino group on the carrier protein. Another popular 
method of conjugation uses a water soluble carbodiimide that acts as a zero length linker and the 
conjugate forms via an amide linker from the carboxyl and amino groupings on the 
polysaccharide and carrier protein. In this investigation three main conjugation strategies were 
examined; the GSK approach using CDAP chemistry, the carbodiimide coupling methodology 
and a triazine approach that has been shown in the past to be very successful with peptide 
coupling. 
The choice of protein is also important.
38
 It was found that the Pn 6B polysaccharide, when 
conjugated to diphtheria toxin CRM197 or tetanus toxoid, induced immunogenicity of higher 
strength than when the 6B polysaccharide was conjugated to diphtheria toxoid or meningococcal 
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protein complex. One possible reason for this could be that the responses to the diphtheria toxin 
CRM197 conjugate and tetanus toxoid conjugate have higher T-cell dependency, which could 
lead to better affinity maturation of the antibodies.
14
 But the same experiment was conducted 
with Pn 14 polysaccharide, and no significant difference in antibody strength was found between 
any of the four conjugates. This clearly suggests that the strength of the antibodies which are 
induced could partly depend on the serotype.38 
The first pneumococcal conjugate vaccine to be licensed was the Prevenar™ or Prevenar™ by 
the Wyeth group in the United Stated of America in the year 2000 and was recommended for 
routine use in children under the age of 2 years,39,40 as a three dose regimen given at 2, 4, and 6 
months, followed by a booster dose at 12 to 15 months (a 3 + 1 schedule) and consisted of seven 
different serotypes conjugated to the cross reactive material 197 (CRM197) carrier protein, a non-
toxic form of diphtheria toxoid (DT) that had already been successfully used in Hib as well as 
meningococcal Group C (MenC) vaccines.  
A significant decline in IPD incidence rates among children under 2 years old was observed 
already in 2001.
41
 This was for protection against Haemophilus influenza type b (Hib) and 
consisted of the capsular polysaccharide of Hib; polyribosyl-ribitol-phosphate (PRP) conjugated 
to diphtheria toxoid via carbodiimide coupling, producing an efficacy against invasive 
pneumococcal disease (IPD) and a vaccine efficacy of 97.4 % was demonstrated when the 
vaccine is administered to infants in a four-dose regimen with three primary immunizations 
during the first year of life with  a booster in the second year of life.
42
 The vaccine contains poly- 
or oligo saccharides from seven Streptococcus pneumonia serotypes (4, 6B, 9V, 14, 18C, 19F 
and 23 F) which accounted for approximately 80 % of IPDs in children under 6 years of age in 
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the United States each conjugated to a genetically detoxified diphtheria toxin CRM 197. Four 
large clinical trials of the 7-valent PCV7 and of a closely related, unlicensed 9-valent PCV9 in 
the USA, South Africa, and  Gambia have reported vaccine efficacies of between 77 % and 97% 
against severe invasive pneumococcal disease caused by vaccine serotypes and of 19 % to 37% 
against radiologically confirmed pneumonia.
43
  
In comparison to PCV7, the 10-valent vaccine (Synflorix) created by GlaxoSmithKline (GSK) 
including the three serotypes 1, 5, 7F in addition to the seven found in Prevnar gives much better 
serotype coverage in Asia, Latin America and Africa and the serotypes contained in Wyeth’s 13-
valent vaccine, covering greater than 80 % of IPD cases in all areas in children under 5 years old. 
Synflorix also used three protein carriers, diphtheria toxoid, tetanus toxoid (TT) and protein D. 
Protein D was used as the carrier protein for 8 out of the 10 serotypes, due to its potential to 
provide protection against Hib infections. GSK used a conjugation method that included first size 
reducing most of the polysaccharides by microfluidization and then activating the polysaccharide 
with 1-cyano-4-dimethylamino-pyridium tetrafluoroborate (CDAP) before coupling the 
polysaccharides to the three proteins. Serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F were conjugated 
to Protein D with serotype 18C conjugated to TT and serotype 19F to DT.
44
 Novel vaccine 
formulations including more conjugated serotypes will be obtainable in future.
45
 There are also 
efforts to establish pneumococcal conjugate vaccines in developing countries. These vaccines 
have to be adequately pre-qualified by the World health Organization (WHO) for use by United 
Nations agencies.
15
 Both PCV7 and the 13-valent vaccine use a non-toxic mutant of diphtheria 
toxin as a carrier protein.46  
Pfizer, in 2010 licensed their 13 valent vaccine that included serotypes 1, 3, 5, 6A, 7F and 19A in 
addition to those covered in PCV-7. Initially it was thought that serotypes 6B and 19F would 
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cross protect for cases of 6A and 19A but this was found not to be the case as incidences of 6A 
and 19A were found to increase after PCV-7 was licensed. Moreover, these two serotypes 
account for more cases of invasive disease than serotypes 1, 3, 5, and 7F combined (8.2 vs. 3.3 
cases/100,000 children 2 years and under). In addition, serotypes 6A and 19A are associated with 
high rates of antibiotic resistance.
47
 Given the relative burden and importance of invasive 
pneumococcal disease due to serotypes 1, 3, 5, 6A, 7F, and 19A, adding these serotypes to the 
Prevnar
®
 formulation would increase coverage for invasive disease to >90% in the US and 
Europe, and as high as 70%-80% in Asia and Latin America. A comparison of the coverage that 
PCV-7 (Prevnar
®
), PCV-10 (Synflorix
™
) and PCV-13 (Prevnar-13
®
) has against IPDs in children 
less than 5 years of age is shown in Table 4. It can be seen that a predicted increase from 48 % to 
76 % and 79 % of coverage against IPDs in Africa has been achieved with PCV-7, PCV-10 and 
PCV-13 respectively. This value globally is predicted to rise from 50 % with PCV-7 to 75 % 
with the introduction of PCV-10 and 77 % with PCV-13. This vaccine would significantly 
expand coverage beyond that of Prevnar
®
, and provide coverage for 6A and 19A that is not 
dependent on the limitations of serogroup cross-protection.
48
 The method for conjugation used in 
PCV-13 was based on the procedure followed for PCV-7 with most of the polysaccharides first 
oxidized with sodium periodate followed by reductive amination to conjugate with CRM197. 
 
Table 4 Licensed pneumococcal vaccines  
Vaccine 
type 
Company 
name 
Serotypes included Protein Licensed date 
Prevnar 
(PCV-7) 
Pfizer 4, 6B, 9V, 14, 18C, 19F, 23F CRM197 2000 
Synflorix 
(PCV-10) 
GSK 
1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 
23F 
Protein D + DT + 
TT 
2009 
Prevnar 13 
(PCV-13) 
Pfizer 
1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 
18C, 19A, 19F, 23F 
CRM197 2010 
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1.6 Technologies  
Capsular polysaccharides are the main antigens involved in the immunity process to 
encapsulated bacteria. The response to capsular PS is T-cell-independent, meaning that B 
lymphocytes proliferate and produce antibodies without the help of T cells. Conjugation which 
couples a PS to a protein carrier, changes the capsular PS from a T-cell-independent antigen to a 
T-cell-dependent antigen.
49,50 
The immune response elicited by this protein antigen uses helper 
T-cells and is thus  T-cell dependent. Helper T-cells enable a more rapid and enhanced immune 
response to occur on re-exposure to an antigen. In this manner, a conjugate vaccine induces 
immunologic memory and provides long-term protective immunity. In addition to increased 
antibody production, an immune response induced by a conjugate vaccine differs from that 
induced by a PS vaccine in the type of antibody produced as well as the effect on nasopharyngeal 
carriage. While some polysaccharides contain chemical grouping which can be conveniently 
utilized for conjugation, eg. amines, carboxyls or aldehydes, many medically important ones 
require derivatization before they can be coupled to a protein.
51,52,53
 This derivatization includes  
oxidation of the primary alcohol moieties  it bears to either the corresponding aldehydes or 
carboxylic acids. The protein is also derivatized in preparation for vaccine production. There are 
approximately 7 different groups on a protein that can be considered for conjugations: Amino 
groups (lysine) which can be conjugated directly to the carboxyl groups on the saccharide,  
carboxyl groups (via aspartic or glutamic acid) which can be conjugated either directly to amino 
groups or first derivatized with ADH and conjugated to the carboxyl groups on the saccharide,  
hydroxyl groups (tyrosine), sulphydryl groups (cysteine), imidazolyl groups found on histidine 
residues, indoylyl groups on tryptophan and finally, guanidyl groups found on arginine amino 
acids. Fig 11 demonstrates via the flow diagram the method most often used in the production of 
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a conjugate vaccine. Starting with fermenting the bacterium (Hib) from which the capsular 
polysaccharide is extracted and purified by the use of column chromatography. Once the pure 
product has been acquired, the polysaccharide is derivatized preparing it to be conjugated to 
derivatized protein (BSA). Once the substrates have been prepared, conjugation follows, with 
purification and analysis by tried and tested assays to confirm vaccine production.  
 
Figure 11 The process of a conjugate vaccine production 
 Conversion of alcohols into their corresponding aldehydes or ketones is a process of major 
importance in fundamental organic synthesis and many methods for this transformation have 
been documented in the literature in view of its significance.
54,55,56 
Numerous transition metal-
catalyzed oxidations of alcohols using aqueous H2O2 or gaseous O2 as a stoiciometric oxidant 
have been developed. Nevertheless, more environmentally benign catalytic and chemoselective 
oxidation methods such as organocatalysis are needed; especially for pharmaceutical processes. 
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The use of heavy metal-based reagents such as KMnO4 and K2Cr2O7 are quite widespread.  
However, not only are these reagents very hazardous with protocols that produce metal wastes 
that require special handling due to their toxic features, but they can only be used for small 
molecules. Therefore, there is a strong need for greener methods that do not require heavy 
metallic species for such transformations as well as water soluble reagents due to the fact that 
polysaccharides are often soluble in aqueous solutions. 
Favorable attributes of an alcohol oxidation procedure include: high conversions, the absence of 
side products, and the use of available, inexpensive, non-toxic reagents, mild conditions, high 
chemo selectivity and compatibility with other functional groups. Often it is necessary to 
selectively oxidize a single primary or secondary alcohol within the same molecule in the 
presence of both. Most commonly used reagents are shown to oxidize secondary alcohols at rates 
slightly faster than primary alcohols, but these have not been practical for selective oxidations 
because of small magnitudes of rate difference.
57
 Despite the availability of a variety of methods 
for such transformations, there is a growing need of green methodologies and over the past 
couple of years, new and environmentally benign oxidation methods have been developed.  
Of the many oxidizing agents that have been used for conversion of alcohols to aldehydes the 
following are included viz., 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO), sodium periodate 
(NaIO4) and hypervalent iodine reagents such as Dess-Martin periodinane (DMP), 
iodoxybenzoic acid (IBX) and its derivatives, Fig 12. These have gained considerable attention 
as mild and selective oxidizing agents.  
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Figure 12 Oxidizing reagents 
The above mentioned compounds are involved in the conjugation reactions of polysaccharides to 
proteins in the development of conjugate vaccines. The next section is dedicated to investigating 
existing and newer technologies. Existing technologies involving CDAP, RA and NaIO4 while 
newer technologies involve Tempo, hypervalent iodine reagents (DMP, IBX and its derivatives)  
1.6.1 EXISTING TECHNOLOGIES 
1.6.1.1- Cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) 
One of the most common methods to activate polysaccharides in preparation for producing 
protein polysaccharide conjugate vaccines is cyanylation with cyanogen bromide (CNBr). 
Cyanogen bromide has been used to activate hydroxyl groups on substances to create reactive 
cyanate esters, which can then be conjugated to ligands containing amine functional groups 
forming an isourea bond as shown in Scheme 1  
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Scheme 1: Reaction of hydroxyl with CNBr and subsequent coupling with an amine functional group. 
 
Activation of hydroxyl groups with CNBr is performed in aqueous media which would then 
eliminate the need for organic solvents. Hydroxyl groups, by themselves do not react 
spontaneously with CNBr. These hydroxyl groups have pKas of approximately 12 and a strong 
base is consequently needed to transform the stable hydroxyl groups (-OH) into the more 
reactive alkoxide ions (-O
-
). These alkoxide ions are much more nucleophilic and are able to 
react with the CNBr by attack at the electrophilic C and expelling Br
-
. However, use of a strong 
base has a large negative effect as both CNBr and the resulting active cyanate esters are rapidly 
hydrolyzed to inert carbamates, resulting in a lower amount of active intermediates to efficiently 
couple to the desired compound. In 1982 Kohn and Wilchek investigated the formation of 
cyanate esters on resins. They determined that instead of increasing the nucleophilicity of the 
hydroxyl groups on the resins it was more useful to try to enhance the electrophilicity of the 
CNBr with the addition of a “cyano-transfer” reagent. Instead of the strong base; NaOH, 
triethylamine (TEA) was used, this allowed for the reaction to occur at neutral pH that then 
avoided formation of the inactive carbamate compounds. As seen in Scheme 2 TEA reacts with 
the CNBr forming a N-cyanotriethylammonium (CTEA) complex that is more electrophilic than 
CNBr by itself and is therefore more susceptible to attack by the hydroxyl functional groups  
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Scheme 2 Formation of an N-cyanotriethylammonium bromide (CTEA) intermediate. 
 
Due to the toxic nature of cyanogen bromide, a less harmful alternative was sort. Although the 
N-cyanotriethylammonium bromide intermediate, compound A in Fig 13, was shown to be a 
suitable alternative to CNBr it was found to be unstable and decayed at -10 °C. By replacing the 
bromide counter ion with a non-nucleophilic ion such as perchlorate (ClO
-
4) or tetrafluoroborate 
(BF
-
4), the intermediate can be obtained as a stable, crystalline compound. The 1-cyano-4-
methylaminopyridinium tetrafluoroborate (CDAP) salt, in Fig 13, was first synthesized in 1976 
by Wakselman and Guibe-Jampel. However it was not used very much until 1983 when Kohn et 
al used the salt to activate a resin consisting of galactose and anhydrogalactose repeating units. 
By substituting CDAP for CNBr, an increase in the activation levels of the resin was seen from 
15 % with CTEA to over 50 % with CDAP, compared to between 1 - 2 % using the traditional 
CNBr activation process with NaOH  
 
Figure 13 Molecular structures of A) CTEA and B) CDAP. 
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The advantages of CDAP over CNBr include the fact that CDAP activation can occur at a much 
lower pH than that of the traditional CNBr-activation.  This allows polysaccharides that are 
sensitive to alkaline conditions to be activated. CDAP has been used to activate a broad range of 
polysaccharides which can then be used either with or without a spacer molecule to conjugate to 
proteins. The activation with CDAP is rapid, as 85 % of the activation was achieved within 5 
seconds and only 120 seconds was needed for the reaction to proceed to completion. Activation 
with CNBr takes between 3-6 minutes. The lower pH and shorter reaction times have been 
thought to reduce the amount of inter- and intrachain crosslinking of the polysaccharides 
hydroxyl groups. 
 
Andrew Lees et al (1996) examined various conditions for activating saccharides with CDAP 
and conjugating them to the BSA protein, with or without a spacer molecule. The activation of 
the polysaccharide in water proceeded with the slow addition of a 100 mg/ml solution of CDAP 
in acetonitrile. The addition was slow as a rapid addition of an organic co-solvent would 
precipitate out the polysaccharide. The activation was over within 30 seconds and the reaction 
pH was raised with 0.2 M TEA. Either the derivatization reagent or the protein was then added 2 
min 30 sec after the CDAP was introduced. Reaction proceeded for at least one hour before 
ethanolamine was added to quench the reaction. Activations with and without the addition of 
TEA were examined where it was seen that the degree of derivatization was reduced by 97 % 
with the absence of TEA. Lees et al also then investigated whether the TEA was essential for the 
activation or whether it simply acted as a weak base. Inorganic buffers, including sodium borate 
and carbonate, as well as NaOH were substituted for TEA to raise the pH after the CDAP 
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activation. As long as the pH is maintained in the basic region of the pH spectrum (7-10), even a 
simple inorganic base can take the place of TEA. 
The CDAP activation approach was then applied to pneumococcal polysaccharide serotypes 6, 
14, 19 and 23. All four of these serotypes had different pH optima to allow for maximum 
activation levels. At Pneumococcal type 6B, which has a phosphodiester linkage, was found to 
have the highest pH at pH 10. All the conjugates prepared exhibited high antibody titers. With 
secondary immunization both the anti-protein and anti-polysaccharide humoral antibody 
responses increased. Lees showed that the concentrations of CDAP and the polysaccharide as 
well as pH were found to be influencing factors in the conjugation procedure.
21
  
 
The CDAP conjugation strategy was used in 2008 by Suarez et al to conjugate pneumococcal 
type 14 to BSA. The conjugate was first dissolved in a sodium borate buffer at pH 9.0, CDAP 
dissolved in a solution of acetone and water was then added and the activation was left to 
proceed for 5 min. The pH was then decreased to 8.3 before the addition of protein. Three 
different proteins: BSA, TT and PLD were each dissolved in a carbonate buffer at pH 8.3 before 
being added to the activated polysaccharide. An excess amount of TT and BSA were added to 
ensure enough nucleophilic groups were available for conjugation but a very small amount of 
PLD was used as it has a lower solubility than the other two proteins at the required pH. The 
reaction was left to proceed at room temperature for 8 hours before being quenched with a Tris-
HCl buffer. This glycoconjugate was then evaluated in mice to determine its immunogenicity 
and succeeded, unlike the polysaccharide on its own, by producing a T-cell dependent response. 
A schematic representation of the reaction discussed above is illustrated in Scheme 3.  
 
 
 
 
 
  
50 
OH
N
C
N
N
H3C CH3
O
C
N
H2O
BF4
-
O
C O
NH2 O O
C C
NH NH
NH NH
(CH2)2OH
Pn 6B
Cyanate 
ester
dilute 
HCl
Triethylamine
Glycine
HO(CH2)-NH2
Quenched 
Active site
Bound
Protein 
conjugate
Isourea 
bond
 
Scheme 3 Mechanism of CDAP conjugation of polysaccharide to protein
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1.6.1.2 Sodium Periodate Oxidation  
Periodate oxidation has been widely used as a routine method for clarification of structures in 
complex carbohydrates, and its earliest applications helped  in the interpretation of  essential 
structures in many polysaccharides.
59
 In 1982 Malaprade observed that periodate ions have a 
selective oxidizing power on the adjacent hydroxyl functional groups (vicinal diols) in acidic, 
neutral or weakly alkaline solutions. Periodate does not oxidize monohydroxy compounds or 
those hydroxylated derivatives from other atoms. In addition to the vicinal diols, other 1,2-
dioxygenated groups and 1,2-amino alcohols
60
 are also oxidatively cleaved by the periodate 
treatment. N-acetylation of the amino group, however, prevents cleavage.
61
 In the total 
qualitative and quantitative determination of carbohydrates, the periodate oxidation method can 
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be used not only for the measurement of the number of vicinal diols but also for the study of 
positions of substituents and/or linkages in derivatives of unknown materials. 
The oxidation of 1,2 diols  with sodium periodate follows the mechanism below, Scheme 4 
 
Scheme 4 The oxidation of 1,2-diols with sodium periodate
62 
Another approach, which was also recognized quite early is the possibility of using periodate to 
introduce dialdehyde functionalities into polysaccharides or glycoproteins. A particularly 
common method in biology and biochemistry is the PAS-(periodate-Schiff base)-staining method 
for carbohydrates, the basis of which is the reaction between the Schiff reagent and the aldehydes 
formed by periodate oxidation.
63
 Formation of aldehyde moieties in the PS by controlled 
periodate oxidation, followed by conjugation to the protein by reductive amination has been one 
of the most industrious methods by which commercially available PS-conjugate vaccines have 
been synthesized.
64
.  
The conjugation strategy of the polysaccharide to the protein (BSA) involved dissolving the 
polysaccharide (50 mg) in purified water and to that, adding a 30-fold molar excess of NaIO4 and 
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then leaving the reaction mixture to stir at room temperature for 2 hour. The reaction is light 
sensitive so it has to be left in the dark. Subsequently quenching the reaction by the addition of 
glycerol (two-molar fold over NaIO4), it was left stirring for a further hour. The mixture was 
submitted to an exhaustive dialysis and lypholized to obtain the product. Fig 14 exemplifies the 
reaction argued. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 Oxidation of PRP with sodium periodate 
The fact that NaIO4 only oxidises vicinal diols is a disadvantage because in cases where no 
vicinal diols are presents, NaIO4 cannot be used. An addition to this limitation is the photo 
sensitivity of the reaction, because it is light sensitive it has to be performed in the dark. 
Furthermore, cleaving the polysaccharide can be detrimental to the molecule therefore avoiding 
such and the above mentioned disadvantages, alternative methods would have to be explored.  
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1.6.1.3 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO) 
The stable, nonconjugated nitroxyl radicals di-tert-butylnitroxyl and 2,2,6,6-
tetramethylpiperidinyloxyl (TEMPO Fig 19) were first reported in the 1960s.
65,66
 Their high 
stability is ascribed to the unpaired electron delocalized over the nitrogen-oxygen bond.
67
 
Recently, these have emerged as metal-free catalysts for selective oxidation of organic 
compounds.
68
 Catalytic oxidation of carbohydrates using the stable nitroxyl radical 2,2,6,6-
tetramethylpiperidine-1-xyl (TEMPO) has become one of the most promising procedures to 
convert polysaccharides into their corresponding polyuronic acids. The method is very suitable 
for selective oxidation of primary alcohol groups to aldehydes and/or carboxylic groups. 
Dissimilar findings to enzymetic or metal-catalyzed oxidation, the TEMPO-oxidation process is 
highly effective for conversion of high molecular weight polysaccharides. Other advantages to 
be mentioned in connection to the TEMPO-oxidation process are: high reaction rate and yield, 
high selectivity and it is a catalytic process
7
. Selectivity is of primary importance in the oxidation 
process. Other functional groups present in a molecule, such as, double bonds should generally 
not be affected under the reaction conditions. Often, the targeted oxidation of secondary 
alongside primary alcohol functions or vice versa is desired, without the respective other 
function being affected. In the synthesis of aldehydes from primary alcohols, carboxylic acids 
are often formed as byproducts of the oxidation reactions (over oxidation) and the oxidation of 
1,2-diols or α-hydroxyketones is frequently accompanied by C-C cleavage reactions.  
Synthesis of TEMPO entails a two-step reaction from the starting material, triacetoneamine. 
Triacetonamine can be reduced using the Wolf-Kishner procedure which involves treatment with 
hydrazine in the presence of a base to yield 2,2,6,6-tetramethylpiperidine which is subsequently 
oxidized to TEMPO by sodium tungstate/hydrogen peroxide Scheme 5.  
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Scheme 5 The synthesis of TEMPO 
 
Scheme 6 Formation of the N-oxoammonium salt 
 Removal of one electron from TEMPO in the presence of a suitable anion yields the 
oxoammonium salt (2,2,6,6-tetramethylpiperidine 1-oxonium) while the addition of one electron  
in the presence of a suitable anion with an acid produces the hydroxylamine (1-hydroxy-2,2,6,6-
tetramethylpiperidium salt Scheme 7.
69
 Golubev, while investigating the method for the 
preparation of oxoammonium salts, discovered that TEMPO in an extraordinarily uneven 
reaction in strong acid is converted to one molecule of the oxonium ion and a molecule of 
piperidium ion.
70
 Several oxidants such sodium hypochlorite (NaOCl) are also able to oxidize the 
“nitroxyl radical” to obtain the corresponding nitrosonium ion, which is the actual oxidant 
Scheme 6.
71
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Scheme 7 Behavior of TEMPO in acids and bases 
 
Following this preliminary oxidation, a nucleophilic attack of the lone pair of electrons of the 
alcohol onto the TEMPO oxoammonium ion takes place to form an adduct. Deprotonation of the 
adduct at the α-C-H bond by a 2-electron movement to form the carbony and the H is picked up 
by an intramolecular transfer to the N-O
- 
to form the reduced form of TEMPO which is oxidized 
by the co-oxidant to regenerate TEMPO Scheme 8.  
 
Scheme 8 Cycle of the Oxidation of alcohols by TEMPO 
Since bacterial polysaccharides usually do not express functional groups that can be readily used 
in the formation of the covalent bond with a protein, avoiding disturbance to the structure of the 
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polysaccharide when formulating a conjugation approach remains the main challenge in such 
reactions.
72
 In most cases, the main purpose of oxidation was to improve the solubility of PSs in 
water. TEMPO oxidation has also been used in the partial oxidation of mannans with the 
immunological properties of the mannans being preserved.
73
 The oxidation of polysaccharides 
with TEMPO, investigated by Zuchao Ma et al 2010, entails the addition of TEMPO and co-
oxidants sodium bromide (NaBr) and NaOCl at a pH of 10 to a solution of polysaccharide in 
water at 0 ºC. The pH value of the solution was kept constant at 10 by continuously adding 0.5 M 
NaOH with the temperature constant at 0 
o
C for a period of up to 24 hrs until a stable pH was 
reached. Subsequently, the reaction was quenched with ethanol and dialyzed with de-ionized 
water over night followed by lyophilization to produce the oxidized product.72 The 
polysaccharides utilized in this reaction were Actinobacillus suis (serotype O:1) and 
Campylobacter jejuni (serotype HS:23,36)  
The conjugation strategy utilized by Zuchao Ma et al of the polysaccharide to the protein (BSA) 
involved dissolving the polysaccharide in MES buffer at pH 5.5 to which EDC was added 
followed by the addition of BSA. The pH of the mixture was adjusted to 5.5 with HCl (0.5 M). 
Keeping the mixture at 23 ºC or 37 ºC for a period of 1-3 days with further dialysis against 
purified water for a further 1-3 days to remove unreacted polysaccharide, EDC and buffer ions 
afforded the conjugate
.72   
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1.6.2 Newer Technologies 
1.6.2.1 Hypervalent iodine oxidizing reagents  
The chemistry of hypervant iodine compounds (λ3 and λ5), with iodine in its third and fifth 
oxidation states, has experienced an extraordinary growth over the past decade.
74
 These 
multivalent iodine reagents are now used broadly in organic synthesis as mild, selective and 
economical alternatives to heavy metal reagents.
75
 Hypervalent iodine reagents, due to their low 
toxicity and ready availability water solubility and cost effectiveness, have attracted considerable 
attention as mild and selective oxidizing agents.
76
 A lot of research has been done on a number 
of hypervalent reagents. Of the various hypervalent Iodine reagents known, 1-hydroxy-1-oxo-
1H-1 λ5-benzo[d][1,2]iodoxol-3-one, commonly referred to as (IBX)77 is the most commonly 
used.
78
  
1.6.2.2. 1-Hydroxy-1-oxo-1H-1 λ5-benzo[d][1,2]iodoxol-3-one (IBX) 
The heterocyclic λ5- iodinane IBX, was discovered by Hartman and Meyer in 1983 and was 
forgotten for over a century due to its remarkable insolubility in most organic solvents. It wasn’t 
until its use to synthesize DMP that the reagent became popular in organic synthesis as a high 
efficient and mild oxidant that can be used for the selective oxidation of primary and secondary 
alcohols and for a variety of other important oxidative transformation.
79
 While the advantages 
such as the ease of use, its environmentally gentle attributes and ready accessibility are all 
positive, IBX’s major drawback, however, is its virtual insolubility in common organic 
solvents.
80
 The insolubility of it in most organic solvents may be attributed to its polymeric 
nature and ionic character.
 
However it readily dissolves in DMSO and therefore almost all 
organic transformations using IBX are carried out in DMSO. Very often, various co-solvents 
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such as THF, acetone, toluene fluorobenzene are used for the oxidation of compounds which do 
not dissolve readily in DMSO.79 It is precisely this property that served to preclude its 
application in organic oxidation reactions for almost a century. In addition to this drawback; both 
reagents are potentially explosive and can therefore not be stored in large quantities. The ever-
growing demand for eco-conscious chemical processes prompted the synthesis of a water soluble 
derivative of IBX that could potentially behave as a green-oxidant capable of oxidising alcohols 
in water.80  The water soluble derivative of IBX is known as modified IBX (mIBX), Fig 15.
81
  
 
Figure 15 Chemical structures of DMP, IBX and mIBX respectively 
While oxidation reactions using both DMP and IBX tolerate the presence of moisture in the 
reaction medium, the presence of large amounts of water when used as a solvent or co solvent, is 
detrimental to the outcome of the oxidation.  This is due to the fact that the mechanisms of 
oxidation with both these oxidizing reagents involve reaction intermediates formed in an 
equilibrium step that is disfavoured with increasing concentrations of water. In addition to this 
drawback, IBX has been found to be highly explosive. Therefore, some researchers have tried to 
solve such problems by: introducing additives to IBX for stabilization and functionalization of 
the arene moiety to increase solubility of IBX in organic solvents or water. Many IBX 
derivatives have been investigated and synthesized for the oxidation of alcohols and are 
illustrated in Fig 16.  
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Figure 16 Hypervalent iodine oxidizing reagents 
 In this thesis however, only the top three of these derivatives will be discussed in depth as well 
as their synthetic procedures.   
Based on the results obtained Frigerio et al regarding the oxidation of alcohols illustrating the 
ability of modified IBX to oxidize allylic/benzyllic alcohols, the lack of oxidation of non-
benzyllic alcohols, the fact that the reaction occurs readily in water, and the noted 
chemoselectivity, a plausible mechanism has been proposed to illustrate the reaction, Scheme 9.
6
 
The significant features of the mechanism entail: an enthalpy favored H-atom abstraction from 
the benzylic site produces the stable α-alkoxy radical 2, which can be oxidized to benzaldehyde 7 
in a single electron transfer (SET) from 2 to the odd-electron species 1, produces the benzylic 
carbocation 3 which upon reaction with water produces  the unstable gem-diol 6 which 
decomposes to give 5 by loss of water.  
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Scheme 9 Plausible mechanism for chemoselective oxidation using mIBX 
 
1.6.2.3 1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (DMP) 
In 1983,  Dess and Martin
82
 found that 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one, 
commonly as known as DMP could be prepared by  treating IBX with acetic anhydride and 
acetic acid Scheme 10. This high valent iodine compound is very soluble in many organic 
solvents and it retains high kinetic stability due to the occurrence of the iodine atom inside a 
stable five-membered ring and surrounded by organic residues.
83
 DMP has a very long lifetime 
under inert atmosphere and room temperature and can be handled with little decomposition in 
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air. When oxidizing alcohols to their corresponding aldehydes and ketones in the solvent 
dichloromethane, the compound is transformed into the organic iodinane and acetic acid.   
 
 
Scheme 10 Formation of DMP from IBX 
The mechanism for oxidation of DMP involves the exchange of acetoxy ligands for alkoxy 
ligands. The periodinane is dissolved in either chloroform or dichloromethane, and the reaction 
is carried out at room temperature. A plausible mechanism is illustrated in Scheme 11. 
 
Scheme 11 Oxidation of an alcohol with DMP 
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The reaction begins with one of the acetoxy groups from the periodinane leaving. It deprotonates 
the 2
o
 alcohol by abstraction of the proton from the H-O bond to form acetic acid and the 
corresponding alkoxide. The negatively charged oxygen of the alkoxide attacks the now 
positively charged iodine. An intermediate iodine-ester complex is formed. The next step is a 
series of electron transfers. One of the attached acetyl groups leaves and deprotonates the ester 
by abstraction of an α-H. The electrons from this carbon-hydrogen bond shift to the C-O  bond 
creating a carbonyl. The electrons from the iodine-oxygen bond are transferred onto the iodine as 
lone pairs. The two resulting species are the oxidized alcohol and a neutral iodine species with 
two lone pairs.  
In addition to small molecules, DMP has also been tested on saccharides by Richard Dyarana et 
al. 
84
 DMP was employed for the introduction of aldehyde functional groups onto target 
molecules. The main concern was to not only oxidize the polysaccharide but to also maintain its 
integrity and minimizing the accompanying degradation reactions.  
The reaction was carried out by dissolving the polysaccharide mannans (50 mg) in 
dimethylsulfoxide. To this, a two-fold molar excess of DMP was added and the mixture 
maintained at room temperature for an hour. Subsequently, the reaction was quenched with 
glycerol (two molar excess over DMP), leaving the solution for a further hour. After dialysis of 
the solution, the precipitated DMP was filtered and the solution was lypholized. The carbonyl 
content was determined by Park-Johnson colorimetric analysis.    
Although at first glance the mechanisms for DMP and IBX appear very similar, these reagents 
have demonstrated differences in reactivity, particularly with 1,2-diols, DMP will cleave the 
glycol bond whereas IBX will oxidize the alcohol but leave the C-C bond intact.  
 
 
 
 
  
63 
Since polysaccharides are water soluble, using IBX and DMP as oxidizing agents could be 
limiting considering their insolubility in aqueous. Therefore, exploring water soluble compounds 
for the oxidation of polysaccharide such as IBX derivatives would be essential.    
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OBJECTIVE: 
The aim of this project is to develop novel hypervalent conjugation strategies towards a 
conjugate vaccine to be employed against pneumococcal type 6B, Fig 17 disease Due to limiting 
amounts of polysaccharide 6B available to Biovac, the investigation of conjugation strategies 
(includes Dess Martin periodinane aldehyde chemistry,
19
 as well as cyanate ester chemistry
20
 
using CDAP) will use polysaccharides isolated from Haemophilus influenzae type B bacteria (for 
Pn1 Hyaluronic acid will be used). The polymer (PRP) contains a phosphodiester linkage and 
has a repeating unit of [←3)-D-α-Ribf-(1→1)-D-Ribitol-(5-P(O→] Fig 18. The conjugates 
produced will be analysed by Size Exclusion Chromatography-High Performance Liquid 
Chromatography (SEC-HPLC), Nuclear Magnetic Resonance (NMR) spectroscopy, if required, 
polysaccharide composition analysis and quantification using colorimetric assays, including the 
ribose (sugar assays) and the Coomassie assay (protein). Bovine serum albumin (BSA) will be 
used as the model protein carrier.   
The objectives of the project thus entail:  
 The synthesis of two hypervalent iodine oxidizing agents for the derivatization of the 
polysaccharide and the analysis thereof using analytical techniques such as:  
o Nuclear Magnetic Resonance (NMR) 
o Infrared Spectroscopy (IR) 
o Mass Spectroscopy (MS) 
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 The development of suitable chemical assays for the verification of derivatized 
polysaccharide/protein 
 The development of a size reduction strategy to size reduce long polysaccharide chains in 
preparation for derivatization 
 The derivatization of pf polysaccharide/protein 
 The conjugation of polysaccharide to protein 
 The verification of the product conjugate by chemical assays as well as analytical 
techniques 
 
Figure 17 Chemical structure of Pn 6B
6 
 
 
 
 
 
 [←3)-D-α-Ribf-(1→1)-D-Ribitol-(5-P(O→] 
Figure 18 Chemical structure of PRP 
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CHAPTER 2 
 
2.1. MATERIALS AND METHODS 
 
Structural elucidation of the organic compounds synthesized was carried out using analytical 
techniques commonly used in the synthesis of organic compounds, namely: 
1. Nuclear Magnetic Resonance Spectroscopy (NMR) 
2. Infrared Spectroscopy (IR) 
3. Mass Spectroscopy (MS) 
The objective of the above analysis was to enable full assignment of spectra and characterization 
of compounds and  in the form of bio conjugated moieties.  
2.1.1 Nuclear Magnetic Resonance (NMR) 
As glycoconjugate vaccines entail the linkage of carbohydrates to carrier proteins, the common 
feature in the production of such is the pre-requisite activation of the polysaccharide for 
conjugation. The capsular polysaccharide used for the purpose of this project is the 
Polyribosylribitol Phosphate (PRP), conjugated to the carrier protein Bovine Serum Albumin 
(BSA).  
One of the crucial quality control tests for the polysaccharide utilized in the production of the 
vaccines is to guarantee that they conform to the specifications placed by the WHO organisation, 
which is their identity and purity.
85
 Methods to establish the identity and purity of the 
polysaccharide have been developed. NMR spectroscopy is one of the techniques that have been 
developed as a means to ascertain the identity of polysaccharides in the manufacturing of 
vaccines. This technique provides a fingerprint characteristic of a structure and is sensitive to 
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small structural differences such as change in a single inter-linkage. The spectra of all the 
capsular polysaccharides that have been studied are quite distinct.
85
 The NMR spectrum of PRP 
is illustrated in Fig 19. Therefor any changes done to PRP when the activation has been carried 
out can be traced.   
 
Figure 19 NMR spectrum of PRP
86 
2.1.2 Infrared Spectroscopy (I.R) 
The activation of the polysaccharide with hypervalent iodine reagents requires first the synthesis 
of the reagents due to their commercial unavailability as mentioned in the previous chapter. With 
synthesis, is it crucial to trace the development of the compounds formed to verify their 
composition and purity. Of the many techniques, IR is one of the commonly used which targets 
the different chemical functional groups in the sample as different functional groups absorb 
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characteristic frequencies of IR radiation which is very useful in that it can accommodate  a wide 
variety of sample types such as gases, liquids and solids. 
  
2.1.3 Mass Spectroscopy (MS) 
Mass spectrometry is one of the most powerful tools in modern chemical analysis due to its 
ability to provide, in most cases, the molecular mass of analytes.  Since it is the standard for trace 
level quantitation of complex mixtures, it is routinely used in the pharmaceutical industry to 
monitor pharmacokinetics and bioavalability of drug compounds in biological matrices.
87,88,89
 
Therefore, this technique is most  useful in the analysis of  polysaccharide and polysaccharide-
protein conjugates. However, not only is it useful for macromolecules, but also for the 
hypervalent iodine organic compounds synthesized. 
 Time-of-flight mass spectrometry (TOF-MS ) is a method of mass spectrometry in which an 
ion's mass-to-charge ratio is determined via a time measurement. Ions are accelerated by an 
electric field of known strength. This acceleration results in an ion having the same kinetic 
energy as any other ion that has the same charge. The velocity of the ion depends on the mass-to-
charge ratio. The time that it subsequently takes for the particle to reach a detector at a known 
distance is measured. This time will depend on the mass-to-charge ratio of the particle (heavier 
particles reach lower speeds). From this time and the known experimental parameters one can 
find the mass-to-charge ratio of the ion.
90
 
Mass spectrometers can be divided into three fundamental parts, namely Fig 20: 
(1) the ionisation source  
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(2)  the analyser  and 
(3)  the detector. 
 
Figure 20 Schematic representation of a mass spectrometer data system
91
  
 
2.2 Colorimetric assays 
A second quality control test for the polysaccharide is its composition. This is determined by 
colorimetric assays developed for different saccharide types. Observing the structure of PRP and 
Pn 6B, it is evident that the repeating units are composed of a ribose structure (PRP) and 
galactose, glucose and rhamnose structures (Pn6B).  
The determination of the presence of either of the compounds above in a solution can be 
achieved by the use of the assays to be discussed below.  
2.2.1 Ribose Assay 
The purpose of the ribose test is to determine the pentose concentration in solutions containing 
polysaccharide or polysaccharide-protein conjugates. It is carried out in various stages of the 
production process, namely:  
 Purified PRP 
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 Activated (oxidised) PRP 
 Conjugated PRP-Activated BSA 
Ribose is determined calorimetrically using a method where strong acid causes hydrolysis of the 
glycocidic and phosphodiester bonds of PRP and release of the moieties. 
The addition of ferric chloride and orcinol gives rise to a characteristics green colour, the 
absorption of which is determined spectrophotometrically at the wavelengths 580 and 670 nm. 
This method is simple, rapid, sensitive and gives reproducible results although care must be 
taken to exclude the presence of sugars other than pentoses as these interfere with the reaction.  
  2.2.1.1 Reagent Preparation 
 10 % FeCl3.6H2O (Reagent A) was prepared by dissolving 1.0 g FeCl3.6H2O in 10 ml of 
distilled H2O (stored in a brown glass bottle at ambient temperature).  
 FeCl3.6H2O/HCl working solution (Reagent B) was made up by diluting 0.5 ml of 
Reagent A to 100 ml with concentrated HCl (stored in a brown glass bottle at ambient 
temperature).  
 4 % orcinol in 95 % ethanol (Reagent C) was made up by dissolving 458 mg orcinol 
monohydrate in 10 ml of 95 % ethanol.  
 The 400 μg/ml ribose stock standard solution was prepared by dissolving 0.1 g of D-(-)-
ribose in 250 ml H2O (store at approximately -20 °C).  
The 40 μg/ml ribose standard working solution was prepared by diluting 10 ml stock standard 
solution to 100 ml with distilled H2O (store at approximately -20 °C).  
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2.2.1.2. Method 
The standards were prepared as in Table 5. 
Table 5 Standards for Ribose assay using Ribose solution 
Tube number  1 2 3 4 5 6 
Water (µl) 500.0 475.0 450.0 375.0 250.0 0.0 
Ribose standard (µl)                     
(µg/m) 
0.0 25.0 50.0 125.0 250.0 500.0 
0 2 4 10 20 40 
The plot of absorbance against concentration (mg/ml) of an assay that has been carried out was 
analysed for linearity using MS excel. The results are shown in Graph 1 along with the 
correlation value.  
 
Graph 1. Ribose calibration curve  
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The measurements were performed in duplicate and were diluted 1:200 before use and 500 μl of 
the sample was placed in each sample tube.  Reagent B, 1 ml, was added followed by 100 μl of 
Reagent C. The tubes were vortexed gently and placed in the 100 °C heating block for 20 
minutes. The samples were then allowed to cool to room temperature and the contents’ 
absorbances were measured at 580 nm and 670 nm. H2O was used as blank. 
Ribose assays were also performed on all conjugates prepared according to the standard 
method.
92
  
2.2.2 Anthrone Assay 
The anthrone assay is a general carbohydrate assay which is used to detect and quantify most 
monosaccharides, such as glucose, galactose and rhamnose. It was developed using glucose as 
the standard and involves acid hydrolysis of all glycosidic bonds to generate monomers and 
dehydration of monomers to give furfuraldehyde derivatives, which react with anthrone to form 
coloured products that are optically active at 625 nm. This assay was applied to Pn 6B 
polysaccharide. Glucose was used to generate a standard curve. 
2.2.2.1. Reagent Preparation 
 A 400 μg/ml glucose standard solution was prepared by dissolving 40 mg of glucose in 
100 ml H2O and diluting 1:10 before use to give a 40 mg glucose standard solution.  
 A 2 mg/ml anthrone solution was made up by dissolving 0.1 g of anthrone in 50 ml 
concentrated H2SO4. This solution was placed in ice at least 30 minutes before use.  
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2.2.2.2 Method 
Duplicate tubes containing 0, 5, 10, 20, 30 and 40 μg glucose standards in 500 μl total volume 
were prepared. This is detailed by Table 6. The sugar sample was diluted with purified H2O to fit 
the glucose standard curve and each dilution sample was made in duplicate. 
Table 6 Standards for Anthrone assay using glucose solution 
Tube number  1 2 3 4 5 6 
Water (µl) 500.0 437.5 375.0 250.0 125.0 0.0 
Glucose standard (µl)                     
(µg/m) 
0.0 62.5 125.0 250.0 375.0 500.0 
0 5 10 20 30 40 
The samples were placed in tubes and were kept on ice for 30-45 min after which 1 ml of the 2 
mg/ml anthrone solution was added dropwise to each tube on ice, with stirring. The solutions 
were allowed to remain on the ice for 10 min. The tubes were then closed and incubated for 16 
minutes a 100º C. Subsequently, the solutions were allowed to cool for 10 min, before the OD of 
the contents of each tube was read at 625 nm using H2O as a blank.
93
 The results shown on 
Graph 2 
 
 
 
 
  
74 
 
Graph 2 Anthrone calibration curve 
2.2.3 Coomassie Assay 
The use of coomassie G-250 dye as a colorimetric reagent is used for the detection and 
quantification of total protein in a sample. In the acidic environment of the reagent, protein binds 
to the coomassie dye.
36
 This results in a spectral shift from the brown form of the dye 
(absorbance maximum at 465nm) to the blue form of the dye (absorbance maximum at 610 
nm).
36
 The difference between the two forms of the dye is greatest at 595 nm and is thus chosen 
as the optimal wavelength to measure the blue color from the coomassie dye-protein complex.
36
 
If desired, the blue color can be measured at any wavelength between 575 nm and 615 nm.
36
  At 
the two extremes (575 nm and 615 nm) there is a loss of about 10% in the measured amount of 
color (absorbance) compared to that obtained at 595 nm.  
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2.2.3.1 Reagent Preparation  
 Coomassie reagent is available with the kit already prepared 
 BSA stock solution is available from the kit 
2.2.3.2 Method 
Working standards containing the BSA solution were prepared as in Table 7:  
Table 7 Standards for Coomassie assay using BSA solution 
Vial A Water (µl) Volume and source 
of BSA (µl) 
Final Concentration 
of BSA (µg/ml) 
A 0 300 of stock  2000 
B 125 375 of stock  1500 
C 325 325 of stock 1000 
D 175 175 of B dilution 750 
E 325 325 of C dilution 500 
F 325 325 of E dilution 250 
G 325 325 of F dilution 125 
H 400 100 of G dilution 25 
I 400 0 0 
 
From Table 7, a set of duplicate tubes were prepared by pipetting 30 (µl) of each of the 
standards, including the unknown sample into the tubes. The Coomassie Reagent (1.5 ml) was 
added to each of the test tubes and mixed well. The samples were incubated at room temperature 
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for 10 min before measuring the absorbance at 595 nm.
94
 The standard curve representing the 
results is shown in Graph 3  
 
Graph 3 Coomassie calibration curve 
2.2.4 TNBS Assay 
This method is carried out to determine hydrazide groups in solutions containing derivatized 
BSA modified with hydrazido linkers. After modification of BSA by introduction of adipic acid 
dihyrazide (ADH), the presence of hydrazide groups, exposed at the free end of ADH is 
measured. This assay can be used to determine unreacted hydrazides present after conjugation of 
derivatized BSA to Pn 6B or PRP.  Trinitrobenzenesulfonic acid (TNBS) forms a purple colour 
with acid hydrazides and an orange colour with primary amines.
37
 Using adipic acid dihydrazide 
as a standard, the molar concentration of hydrazides can be determined which can be converted 
into moles hydrazides per mole BSA or, considering BSA contains a total of 99 carboxyl groups 
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(from Asp and Glu), as percentage activation (mole fraction of carboxyls converted to acid 
hydrazides) can be determined. 
2.2.4.1 Reagent Preparation  
 An ADH (2.5 mM) standard solution was prepared by dissolving ADH (0.435 g) in 
purified water (100 ml). The mixture was mixed until homogenous and diluted 1/10 to 
give the final concentration. 
 An acetylhydrazide (2.5 mM) standard solution was prepared by dissolving 
acetylhydrazide (0.1825 g) in purified water (100 ml). The mixture was mixed until 
homogenous and diluted 1/10 to give the final concentration.  
 A TNBS solution (0.1%) was prepared by diluting a 5 % TNBS solution (500 µl) to 25 
ml by purified water. The solution was prepared fresh before use.  
 A 10 % HCl solution was prepared by dilution of concentrated HCl (13.5 ml) to 50 ml 
distilled water.  
A 0.1 N borate buffer solution at pH 9.0 was prepared by dissolving sodium tetraborate (1.9 g) in 
purified water (40 ml). The pH was adjusted to 9.0 by HCl (10 %) and the solution was diluted to 
50 ml with distilled water. 
2.2.4.2 Method  
Duplicate tubes containing ADH standards representing the standard curve were prepared 
according to Table 8:  
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Table 8 Standards for TNBS assay using ADH solution 
Tube number 1 2 3 4 5 6 
Water (µl) 500 484.4 468.8 437.5 415 375 
ADH standard (µl) 
(mM)     
0 15.6 31.2 62.5 85 125 
0 0.0781 0.156 0.3125 0.425 0.625 
 
Along with the standard curve was included an acetylhydrazide control standard which was 
prepared by diluting acetylhydrazide (2.5 mM)  to a working concentration of 0.625 mM.  The 
BSA samples under investigation were diluted to fit the standard curve. To all the tubes, 0.1 N 
borate buffer, pH 9.0 (1 ml) was added, as well as 0.1 % TNBS (500 µl) respectively. The tubes 
were mixed thoroughly and incubated at 20-25 ºC for 2 hours. Subsequently, the OD’s of the 
samples were measured at 550 and 750 nm.
95
  
2.2.5 BCA –Aldehyde Assay 
PRP is oxidised in the presence of an oxidising agent to give oligosaccharides terminating with 
aldehyde groups at both ends. The (Bicinchoninc Acid) BCA Assay was developed to quantify 
the amount of aldehydes generated.  
In this assay, a copper (Cu) solution is reduced by aldehydes from Cu
++
 to Cu
+
. The Cu
+
 forms a 
distinctive purple coloured complex with the BCA solution. The coloured complex can be 
detected using a spectrophotometer at 562 nm where it has a maximum absorbance. The 
formation of the coloured Cu
+
-BCA complex is proportional to the aldehyde concentration 
present.  
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Glycoaldehyde (dimer with two aldehydes per molecule) and Ribose are both used with a known 
concentration to quantify the amount of aldehydes in oxidised PRP. The reason two standards are 
used, as opposed to one, is that neither standards gives a definitive aldehyde value. The true 
aldehyde concentration lies somewhere in between the two standard values. As a consequence of 
this, the aldehyde concentration of the sample is read from the graphs of both standard solution 
and the average is calculated between the two.   
2.2.5.1 Reagent Preparation  
 A ribose standard (1 mM) was prepared by dissolving ribose (0.015 g) with purified 
water in a 100 ml volumetric flask and mixed well.   
 A glycoaldehyde standard (0.5 mM) as prepared by dissolving glycoaldehyde (0.006 g) 
with purified water in a 100 ml volumetric flask and mixed well 
 A BCA™   Protein Assay Reagent A solution was available with the kit  
  A BCA™ Protein Assay Reagent B solution was available with the kit  
  A BCA™ Protein Assay Reagent working solution was prepared by adding 50 parts of 
BCA ™ Protein Assay Reagent A and 1 part BCATM Protein Assay Reagent B . A 
precipitate formed after adding Reagent B but easily dissolved after mixing.   
2.2.5.6 Method 
Duplicate tubes containing Ribose and Glycoaldehyde standards were prepared and are 
illustrated in Table 9.  
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Table 9 Standard for BCA Aldeyhyde assay using Ribose solution 
Tube number 1 2 3 4 5 6 7 
Water (µl) 500 490 475 450 425 400 375 
Ribose (µl) 
Standard (µg/ml) 
0 10 25 50 75 100 125 
0 0.02 0.05 0.10 0.15 0.20 0.25 
Tube number 1 2 3 4 5 6 7 
Water (µl) 500 490 475 450 425 400 375 
Glycoaldehyde (µl) 
Standard (µg/ml) 
0 10 25 50 75 100 125 
0 0.02 0.05 0.10 0.15 0.20 0.25 
 
The samples under study were diluted to the polysaccharide concentration of ~1.5-2 mg/ml in  a 
volume of 500 µl. To each of the test tubes, BCA
TM 
Protein Assay Reagent working solution 
(1000 µl) was added. After vigorous mixing, the samples were incubated for 90 min at 60 ºC. 
Subsequently, they were allowed to cool for 10 min before taking the absorbencies at both 562 
and 750 nm (Graphs 4 and 5 respectively).
96
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Graph 4 BCA aldehyde calibration curve measured at 562 nm  
y = 5.6053x + 0.0044
R² = 0.9961
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
0 0.05 0.1 0.15 0.2 0.25 0.3
A
b
s
o
rb
a
n
c
e
Aldehyde concentration (mM)
BCA aldehyde Assay
 
Graph 5 BCA aldehyde calibration curve measured at 750 nm. 
2.2.6 MBTH Assay 
The current method for detection of aldehydes (BCA-aldehyde assay) uses the chromogen 
BCA to determine the presence of aldehydes at wavelengths of 562 and 750 nm. The 
wavelength of 562 nm is commonly used in the BCA protein assay to quantify protein 
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concentrations. Therefore using the BCA-aldehyde assay method to detect residual aldehydes 
in the presence of proteins (conjugated vaccines) may lead to the assay over estimating the 
amount of aldehydes presence as it will also detect the presence of the carrier protein.  
Therefore, developing a method to detect residual aldehydes in the presence of proteins is 
essential. In the presence of an oxidising agent, FeCl3, MBTH binds to an aldehyde group 
which results in a characteristically blue coloured solution which is detected using a 
spectrophotometer at 619 nm. Using the MBTH assay, residual aldehyde concentrations in 
samples containing Hib conjugates can be determined from a linearity curve using 
glycoaldehyde as a standard. 
2.2.6.1 Reagent Preparation 
 A glycoaldehyde standard solution (25 mM) was prepared by dissolving glycoaldehyde 
(0.3 g) in purified water (100 ml). The mixture was mixed until it was homogenous.  
 A MBTH solution (0.2 %) was prepared by dissolving MBTH (0.2 g) in purified water 
(100 ml). The mixture was mixed until homogenous. 
 A ferric chloride solution, FeCl3.6H2O (0.1 %) was prepared by dissolving FeCl3.6H2O in 
purified water. The mixture was mixed until homogenous.  
2.2.6.2 Method  
Duplicate tubes containing the glycoaldehyde (25 mM) standard representing the standard curve 
were prepared as demonstrated in Table 10.   
 
 
 
 
 
  
83 
Table 10 Standards for MBTH assay using glycoaldehyde solution 
Tube number 1 2 3 4 5 6 
Water (µl) 1800 1798.4 1796.8 1793.6 1787.2 1775 
Glycoaldehyde Std (µl)          
(Mm) 
0 1.6 3.2 6.4 12.8 25 
0 1.6 3.2 6.4 12.8 25 
The oxidised PRP samples were diluted to a PRP concentration of 36.12 or 40.1 µg/ml or in 
between in duplicate. To all the tubes was added 0.2 % MBTH solution (0.4 ml) followed by 0.1 
% FeCl3.6H2O (0.4 ml) and mixed gently. The samples were incubated at 20-25 ºC for 0 min. 
Subsequently, purified water (2.4 ml) was added to all the tubes and mixed gently before reading 
the absorbencies at 619 nm (Graph 6).
97
   
  
Graph 6 DOC calibration curve 
2.2.7 DOC Assay  
The reliable determination of unconjugated polysaccharide (Pn6B/PRP) is an important factor in 
the quality control of conjugate vaccines. The WHO TRS for HIB conjugate vaccines specifies 
that the percentage unconjugated PRP should be between 10 – 40 % and therefore a sensitive and 
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reliable method for the determination and separation of unconjugated polysaccharides from the 
conjugated sugar is desired.   
This method constitutes an adaptation of a method first developed by Siber et al.
98
 The method is 
based on the differences between acid precipitation properties of the  PRP-BSA conjugate and 
the PRP alone. The principle of this method is that proteins have no overall charge and minimum 
solubility at their isoelectric point. Aggregates can form as the pH is adjusted to approach the pI 
of the protein and these aggregates can be collected by centrifugation. Based on this principle, 
the PRP-TT conjugate is precipitated under acidic conditions using acidic deoxycholic acid 
(DOC) as it reaches its isoelectric point thus leaving unconjugated polysaccharides in the 
supernatant.  
2.2.7.1 Reagent preparation    
 HCl (1 M) was prepared by diluting concentrated HCl with purified water 
 Sodium chloride (0.15 M) was prepared by dissolving sodium chloride (8.77 g) into a 
1000 ml glass beaker containing a stirrer bar. To this was added purified water (800 ml) 
and the mixture was stirred to dissolve the contents. Subsequently, the solution was 
diluted up to 1000 ml with purified water.  
1 % w/v DOC at pH 6.8 was prepared by dissolving 0.10 g DOC in purified water (10 ml) in a 
25 ml glass beaker. The mixture was mixed using a plastic pasture pipette until the DOC had 
dissolved. The pH of the solution was adjusted with HCl (1 M) until it was between the range 
6.75 – 6.82. Two drops of HCl (1 M) were enough for the 10 ml solution. 
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 2.2.7.2 Method    
 The total polysaccharide concentrations in each sample were determined separately using 
(the ribose assay for PRP, the anthrone assay for Pn 6B).  
 Once the concentration was known, the samples were diluted to provide a total 
polysaccharide concentration of approximately 75-700 µg/ml using NaCl (0.15 M).  
 Successively, 1 ml of each of the diluted samples, containing approximately 15-100 µg 
total polysaccharide, were delivered into conical micro-centrifuge tubes, along with a 
“precipitation blank containing purified water (1 ml) and a “gold standard” containing 
just the polysaccharide (1 ml). All samples for analysis were prepared in duplicate.  
 To each tube, 1 % w/v DOC reagent (100 µl) was added, vortexed for approximately 10 
seconds and kept at 2-8 ºC for 30 min.  
 After the 30 min, 1 M HCl (50 µl) was added to each tube, vortexed  for  approximately 
10 min and centrifuged for 30 minutes at 13 400 rpm.  
 The precipitation that formed was discarded and the supernatants were transferred into 
separate tubes and assayed using the appropriate polysaccharide assays.  
The purpose of this analysis is to determine the percentage of unconjugated sugar remaining in 
the final PRP-BSA (or Pn6B) bulk conjugate. The PRP-BSA (or Pn6B) conjugate is precipitated 
under acidic conditions using sodium deoxycholic acid (DOC). The solution is centrifuged and 
the unconjugated PRP remaining in the supernatant is quantified using a ribose assay. This value 
is expressed as a percentage of the total PRP in the conjugate. 
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The experimental procedure of this assay is as follows: 
 After the total concentration of PRP has been determined, separately, with the use of the 
ribose assay, the known concentration of the samples is diluted to approximately (75-100 
µg/ml) using a PBS (10 mM) solution, samples are analysed in duplicates.  
 Upon dilution, the diluted samples (1 ml) are transferred into conical micro-centrifuge 
tubes. Amongst these samples, a blank, water and a PRP gold standard are also prepared.  
 A DOC (1 % w/v) reagent, freshly prepared is added to each of the tubes and the 
mixtures are thoroughly mixed for approximately 10 seconds.  
 The samples are then stored at 2-8 ºC for 30 minutes after which 1 M HCl (50 µl) is 
added to each tube and thoroughly mixed for 10 seconds.  
 The samples are centrifuged for 30 minutes at 13 400 rpm. The precipitate will remain at 
the bottom of the tube and the supernatant is transferred into separate tubes.  DOC works 
by precipitating all protein, whether conjugated or not conjugated, hence leaving free PS 
in the supernatant for analysis.  
 These supernatants are then assayed using the ribose assay.99  
Assays are sufficient to check the quality of polysaccharides and to track the conjugation 
process. The assays presented here are well known and are widely applied in vaccine research, 
the ensure reliability and consistent results.   
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2.3 Size Reduction 
Size reduction of polysaccharide is a well reported process and there is more than one method to 
achieve this such as sonication and hydrolysis. For our process we investigated the use of a 
microfluidics processor unit. Monitoring size reduction is complex for long chain 
polysaccharides. This is because not only is size reduction crucial, but also the conservation of 
mass post size reduction, effects in polysaccharide integrity and polydispersity are all equally 
important.  For our purpose as mentioned before in the introduction, we employed polyribosyl 
ribitol phosphate, [←3)-D-α-Ribf-(1→1)-D-Ribitol-(5-P(O→], (PRP) as the model 
polysaccharide. The microfluidizer processor unit was purchased from Microfluidics in 
Germany. The M-110P model consists of 250 ml reservoir, piston pump with a pressure range 
(0-3500 psi), pressure gauge, diamond interaction chamber and a cooling loop and will be 
discussed in detail later. Before exploring results on the microfluidizer, it was decided to review 
the alternate methods, such as hydrolysis and sonication, and to investigate the pros and cons of 
each method.  
2.3.1.1 Hydrolysis 
Hydrolysis is a chemical process in which a molecule is split into two parts by the addition of a 
molecule of water. One fragment of the parent molecule gains a hydrogen ion (H
+
) from the 
additional water molecule. The other group collects the remaining hydroxyl group (OH
−
). In 
polysaccharides, hydrolysis is done to degrade a long polysaccharide chain into its 
oligosaccharide fragments (ie. it’s repeating units) or even its monosaccharide constituents.100 
The method of hydrolysis employs either an acid or base as catalyst. Acid–base-catalyzed 
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hydrolyses are very commonly encountered in nature and in the laboratory and examples include 
the hydrolysis of amides and esters. Their hydrolysis occurs when the nucleophile attacks the 
carbon of the carbonyl group of the ester or amide. In an aqueous base, hydroxyl ions are better 
nucleophiles than water. In acid, the carbonyl group becomes protonated, and this leads to a 
much easier nucleophilic attack by the water molecule.  
The procedure essentially involves dissolving the polymer in the buffer and holding the solution 
at the desired hydrolysis temperature while removing samples periodically for analysis.
101
 The 
advantage of using acid/base hydrolysis is that it is a chemically cheap method and it requires no 
heavy instrumentation. The drawback of this method however is that, since hydrolysis is either 
acid or base dependent, the polysaccharide to be hydrolysed should not have any functional 
groups that are sensitive to either acid or base depending on which method is being utilized. If 
this is the case, then not only will the polysaccharide be size reduced, but the acid may 
additionally detach one or all the functional groups from the polymer thereby changing its 
structural integrity. This is a very sensitive case because it is important that the integrity of the 
repeating unit remains intact post microfluidization.  
 
2.3.1.2 Sonication 
The second interesting size reduction method is sonication. This method is widely reported and 
used for reduction of complex PS with large success. The primary part of a sonication device is 
the ultrasonic electric generator.
102
 This device creates a signal (usually around 20 KHz) that 
powers a transducer (Fig 21). In turn the transducer converts the electric signal by using 
piezoelectric crystals, or crystals that respond directly to the electricity by creating a mechanical 
vibration. The vibration, molecular in origin, is carefully preserved and amplified by the 
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sonicator, until it passes through to the probe. The sonication probe transmits the vibration to the 
solution being sonicated and consists of a carefully constructed tip that moves in time with the 
vibration, transmitting it into the solution. The probe can move up and down at a very high rate 
of speed, although the amplitude can be controlled by the operator and is chosen based on the 
quantity of the sample solution being sonicated.102 
 
 
Figure 21 Ultra Sonicator processor unit
102
 
 
One example of a drawback where sonication is concerned is that, the probe, after it has been 
operating for a considerable amount of time starts shedding metal particles from its tip into the 
solution being analysed. These metal particles can be filtered through a 0.22 µm vent filter but 
one would still have to be validate the complete removal of metal particles shed  by long term 
usage.  Another drawback is that the sample liquid localised close to the tip of the probe heats up 
and the sample is exposed to excessive localised heat for long periods. However, a positive 
aspect of sonication is that no change is observed in structural integrity of the polysaccharide as 
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proved by GC-MS and HPLC analysis. This might cause some interference to the 
chromatograms of the HPLC when analysing the different sizes obtained after sonication.   
2.3.1.3 Microfluidization 
The mechanism through which size reduction is achieved is microfluidization. The effect of 
reconstituting PRP in  different buffers would also need to be evaluated. It is well known that the 
hydrodynamic size of PRP changes depending on what aqueous environment the polysaccharide 
is in. For this reason, water, 0.2 M NaCl and 10 mM PBS buffers will be used to evaluate the 
effect of a buffer in the size of the polysaccharide.  To depolymerize a polysaccharide chain 
without altering its chemical structure and degree of substitution is of great interest. When 
polymer solutions are sheared, agitated or extruded, mechanical stress is created on the polymer 
molecules. If the stress reaches beyond a critical level, polymer chains can be broken, leading to 
formation of macroradicals which may then react to form shorter or modified polymer 
molecules. Polymers having heteroatoms in their backbone, such as polysaccharides and proteins 
can also undergo fission with the formation of polymeric ions  
 
 
 
 
Figure 22 M-110P bench-top Microfluidizer
®
 processor.
103
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Microfluidization operates by a different mechanism to sonication. Microfluidizers contain a 
double-acting intensifier pump and an interaction chamber (Fig 22). The intensifier pump may be 
air-driven or electric- hydraulic driven and consequently provides a high pressure to force the 
product through the interaction chamber. The reaction chamber is built in such a way that the 
liquid is divided into two microstreams that are projected against one another at high speed and 
at an angle of 180º.
104
 These streams collide with each other causing them to shear  and the  
impact that occurs  forms emulsions with very small particles. A cooling coil after the interaction 
chamber may or may not be present (Fig 23).   
 
Figure 23 Schematic representation of the reaction chamber of the microfluidics equipment
104
 
2.3.2 High Performance Liquid Chromatography (HPLC) 
Size Exclusion Chromatography – High Performance Liquid Chromatography (SEC- HPLC) is 
the analysis of molecules using chromatography where particles are separated based on their 
size. It is usually applied to large molecules or macromolecular complexes such as proteins and 
polymers. This method is one of the most important and indicative tools for in-process 
monitoring. It is used to determine the molecular size distribution of a conjugate and provides a 
critical tool for determining manufacturing consistency during the production process.  
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Post fermentation of Hib and downstream processing involves a series of steps to generate 
polyribosylribitol phosphate (PRP) that is low in both endotoxin and nucleic acid. The capsular 
polysaccharide (PRP) is then further processed for incorporation into the conjugate vaccine. PRP 
is a long chain polymer and as specified by WHO it is necessary to measure the length of the 
polysaccharide as well as the molecular size distribution. After the polysaccharide has been 
oxidized, SEC-HPLC is used to determine the extent of size reduction of the oxidized PRP as 
well as the molecular size distribution. During conjugation, it is used to monitor the extent of 
conjugation and the final conjugate is analysed for molecular size distribution as specified by 
WHO.     
The SEC columns used for SEC-HPLC are the most critical parameters requiring optimisation 
when setting up a SEC-HPLC method. The column must have a fractionation range suitable for 
both high molecular weight polysaccharides and proteins and size reduces polysaccharides as it 
is required for monitoring full length PRP before oxidation, size reduced low molecular weight 
PRP after oxidation as well as large molecular weight conjugates. 
2.3.2.1 Raw Materials 
 DNA Molecular weight II marker, Roche. Before opening it is stored at -20 ºC, after it 
has been opened it is stored at 4 ºC 
 Pullulan standards, Shodex P-82, Anatech. Once opened it is stored in a dessicator at 
maximum temperature of 25 ºC 
 Ethylene Glycol, Material Code E003, MW 62.07 g/mol, density 1.11 g/mL, min. 
pharmacopoeia grade. Stored at room temperature 20-25 ºC 
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 Sodium Azide 99.99 %, FW = 65.01 g/mol, Sigma Aldrich, HPLC grade. Stored at room 
temperature 
 Di sodium Hydrogen Phosphate. Min 99 %, FW = 141.96 g/mol. Saarchem. Stored at 
room temperature  
 Hydrochloric acid, 37 % fuming. Merck 
 Sodium Hydroxide. Min 98.0 %, FW = 40 g/mol. Saarchem     
2.3.2.2 Preparation of standards, controls and working reagents 
 Preparation of reagents 
o Reagent A, 1 M NaOH 
 NaOH (2.0 g) was dissolved in purified water to a final volume of 500 mL 
and stored at room temperature 
o Reagent B, 1 M HCl 
 Concentrated HCl (8.25 ml) was mixed with purified water to a final 
volume of 1000 ml and stored at room temperature. 
o Reagent C, 0.2 M NaNO3 
 NaNO3 (16.998 g) was dissolved in purified water to a final volume of 
1000 ml and stored at room temperatures 
o Reagent D, 0.1 M Na2HPO4
-
 
 Na2HPO4 (12.200 g) was dissolved in purified water to a final volume of 
1000 ml and stored at room temperature.  
o Reagent E, 0.1 M NaNO3. 0.001 M Na2HPO4, pH 7.0 
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 Reagent D (100 ml) was diluted with purified water to 1000 mL to give 
the final concentration of 0.01 M Na2HPO4. This was mixed with 1000 ml 
reagent C and the pH was adjusted to pH 7.00 with reagent B. This was 
filtered under vacuum through a 0.45 µm membrane and stored at room 
temperature.  
o Reagent F, 0.05 % w/v NaN3 
 NaN3 (2.5 g) was dissolved to 5 L with purified water, filtered under 
vacuum through  a 0.45 µm membrane and stored at room temperature in 
an amber glass bottle.   
2.3.2.3 Preparation of standard solutions  
 Pullulan stock Standard solution 2 mg/ml  
o Add n mL reagent E slowly to 2n mg P-5 (or other pullulan standard) in a clear 
glass tube. Do not mix. Leave the tube to stand overnight at ~4 ºC. The next day, 
gently mix the tube by inverting several times.  Divide into smaller portions (eg. 1 
mL) and store at ~20 ºC 
o Pullulan mix I standard solution (P-10, P-5, P-200 and P-800, 0.5 mg/mL each): 
Mix 1 mL each of P-10, P-50, P-200 and P-800 pullulan stock standard solutions.  
Divide in small portions and store at ~20 ºC 
o Pullulan mix II standard solution (P-5, P-20, P-100 and P-400: 0.5 mg/mL each): 
Mix 1 mL each of P-5, P-20, P-100 and P-400 pullulan stock standard solutions.  
Divide in small portions and store at ~20 ºC 
 Sodium Azide standard solution 2 mg/mL 
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o Add n ml reagent E to 2n mg sodium azide. Filter through a 0.22 µm membrane. 
Store in an amber glass bottle. Use within 1 month 
o DNA Molecular Weight Marker II 100 µg/mL: Add 100 µl of the stock DNA 
molecular weight marker (250 µ/mL) to a 150 µl reagent E with the final volume 
250  µl. Mix well and store at 2-8 ºC 
o 1 % Ethylene Glycol: Mix 10 µl ethylene glycol with 990 µl reagent E making the 
final volume of 1000 µl and mmix well. This is prepared freshly before use. 
The columns used for this experiment are the Shodex OH Pak SB 805-804 columns. Factors 
investigated with these columns included mobile phase selection, calibration standards and 
optimal sample concentration. The standards used for calibration of the HPLC were Shodex P-82 
Pullulan standards. The standards have a more appropriate molecular weight range and bear a 
close resemblance to long chain polysaccharides (Table 11). 
Table 11 Molecular weights of Pullulan standards 
Standard Elution Time Molecular Weigh (Da) 
800 13.129 788 
400 13.802 404 
200 15.077 212 
100 16.106 112 
50 17.215 47.3 
20 18.21 22.8 
10 18.878 11.8 
5 19.490 5.9 
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Figure 24 RID signal of Pullulan mix 1 and 2, showing the retention times of individual molecular weight 
peak 
The Mw calibration curve was obtained (Fig 24) by plotting Ve (y-axis)versus log Mr (x-axis). 
The calibration curve should a third degree polynomial equation:  
Log Mr = K3 × Ve
3
 + K2 × Ve
2
 + K1 × Ve + Ko 
 Ve is the elution volume (in ml or in M=min as Rt) 
 K3, K2, K1 and Ko are constants determined by the graph 
Samples were all found to elute within the fractionation range of the columns.  
Void and total volumes for the columns were determined using DNA molecular weight marker II 
and sodium azide respectively Table 12. An example of the sodium azide chromatogram is 
shown in Fig 25, the DNA molecular weight marker II in Fig 26.  
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Table 12 Samples run on Shodex OH Pak SB 805-804 columns 
Mobile Phase: 10mM PBS pH 6.8 
Flow rate : 1ml/min 
RID and DAD 
Compound Concentration Elution time Comment 
Sodium Azide 25 mg/ml 22.676 min Used to calculate Vt 
DNA molecular weight marker II 0.25 mg/ml  Used to calculate Vo 
 
 
Figure 25 Sodium Azide peak. Elution time used to calculate Vt 
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Figure 26 Molecular Weight Marker used to calculate Vo 
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CHAPTER 3 
SYNTHESIS RESULTS AND DISCUSSION 
3.1 Retrosynthetic analysis of Modified O-Methyl substituted-1-hydroxy-1,2-
benziodoxol-3(1H)-one-1-oxide 
A retrosynthetic overview of the key strategic disconnections is depicted in Fig 38. Since 
Hartman and Meyer, who were responsible for the synthesis of IBX have already shown that 2 
may be converted to 1 via the oxidation of 2 by either oxone or KBrO3
105
, it seemed logical to 
first target the synthesis of compound 2. It was furthermore established that the functional group 
interconversion of a -CH3 to a CO2H (i.e. 3 transformed into 2) by oxidation of the former to the 
latter using a strong oxidizing agent such as KMnO4 and KCr2O3, this would suggest the 
precursor to be 4-iodo-3,5-dimethylanisole 3 which in turn could be obtained from phenol 4  and 
this molecule could be secured by iodination of  3,5-dimethylphenol 5 through electrophilic 
aromatic halogenation, which is a commonly known reaction Scheme 12.
106
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Scheme 12 The retrosynthesis of Me-IBX 
 
3.2 A proposed synthesis of Modified O-Methyl substituted-1-hydroxy-1,2-
benziodoxol-3(1H)-one 1-oxide 
The synthesis of the hypervalent iodine compound Me-IBX, commenced from commercially 
available 3,5-dimethylphenol  5 by iodination  to yield 4-iodo-3,5-dimethylphenol 4. This is 
followed by methylation to yield 4-iodo-3,5-dimethylanisole 3 according to the publication by 
Jarangu, Narasimha, Moorthy et al.  Oxidation of 3 with KMnO4 afforded the precursor, 2-iodo-
3-methyl-5-methoxybenzoic acid 2 (after chromatographic separation from the dicarboxylic acid 
analogue 2a), of the final product Me-IBX 1 which was obtained by further oxidation of 2 with 
oxone 
107
 and is illustrated in Scheme 13. 
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Scheme 13 Reagents and conditions: (i) KIO3, KI, MeOH, HCl, 0 ºC, 0.5 h, 60 %; (ii) MeI (2 equiv), KOH, DMSO, 
25 ºC, 2 h, 95 %, (iii) KMnO4 (7 equiv), pyridine, H2O, reflux, 1.5 h, 16 %, (iv) oxone, (1.5 eqiv), H2O, 70 ºC, 33 %. 
   
3.3. Synthesis of synthons 1, 2, 3, 4 and 5 
The first step towards the synthesis of Me-IBX was the iodination of 3,5-dimethylphenol which 
was achieved by treating phenol 5, with an access of a solution of KI/KIO3 in water at 0 ºC for 
30 min. The 
1
HNMR spectrum (Fig 27) obtained exhibited a 6-proton  signal at δ 2.39 ppm, 
attributable to the methyl groups and a 2-proton  signal at δ 6.59 ppm attributable to the aromatic 
protons H-6 and H-4 indicating that the compound obtained was  symmetrical suggesting that the 
iodo group was on C-4. However it is important to note that the functional groups on the 
aromatic ring are all electron donating and will therefore direct any incoming electrophile to 
either the ortho and/or para position. This results in all of the accessible ring positions having an 
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equal basis to be attacked by the iodine and followed by elimination of a proton through the 
Wheland intermediate. However the para position relative to the OH is the more reactive and is 
the one attacked. 
13
C NMR spectrum (Fig 28) on the other hand illustrates for the C-I peak 
observed at 96.968 ppm that was not present in the NMR of the starting material. The IR 
spectrum reveals the presence of C=C vibrational frequency at νmax 1579 cm
-1
 and a broad 
absorption band at νmax 3287 cm
-1
 the latter of which is attributable to the OH group. The MS 
confirms the presence of the compound 4-iodo-3,5-dimethylphenol with the calculated mass 
peak 248.06 g/mol, with  a found peak at m/z 247.1668 (M
+
) being the parental peak. The 
product was filtered off under vacuum, washed with purified water and dried in an oven at 60 C 
overnight. 
 
Figure 27 
1
H NMR Spectrum of 4-iodo-3,5-dimethylphenol 
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Figure 28 
13
C NMR Spectrum of 4-iodo-3,5-dimethylphenol 
The succeeding step was the methylation of 4, which was achieved by treating 4, in dimethyl 
sulfoxide, with a two molar-fold excess of methyl-iodide in the presence of a base, KOH, at 
room temperature for 2h. Upon extracting the organic layer with petroleum ether, washing it with 
brine and drying with magnesium sulphate, the expected product 3 was obtained with a high 
yield of 95 %. Therefore, a new signal at δ 3.76 ppm is observed in the 1H NMR spectrum of 4-
iodo-3,5-dimethylanisole 3 due to the methoxy group which is confirmed in the 
13
C NMR 
spectrum  by a new signal at δ 55.2 ppm for the methoxy group. 
This was followed by oxidation of 3 in pyridine with potassium permanganate, KMNO4, in an 
excess of water at 100 ºC. Despite its unsaturation, the benzene ring is inert to strong oxidising 
agents such as KMnO4 that would cleave the alkene C-C bonds. However, the presence of an 
aromatic ring has a dramatic effect on alkyl group side chains. Alkyl side chains are readily 
targeted by oxidising agents and are converted into carboxyl groups. 
108
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The proposed mechanism of alkyl side chain oxidation on an aromatic rings involving potassium 
permanganate is rather complicated and is shown in Schemes 14 and 15.  
 
Scheme 14 Formation of the active form (MnO3
+
) of the permanganate ion 
109
 
 
Scheme 15 Oxidation of alkyl side chains by potassium permanganate in acidic medium
110
 
In the reaction represented above Scheme 15, two products were obtained in the oxidation of the 
starting material with KMnO4. In principle, both alkyl groups are amenable to KMnO4 
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oxidations, not merely one which is the desired product. Separating such compounds is a rather 
difficult task, which was achieved by silica gel column chromatography                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
with the use of EtOAc/Hex 60 % as the eluent.  The 
1
H NMR spectrum Fig 29 for the desired 
compound, 2-iodo-3-methyl-5-methoxybenzoic acid, illustrates two chemical shifts at 6.07 and 
6.240 ppm attributable to H-4 and H-6 respectively. The signal at 28.8 ppm in the 
13
C NMR 
spectrum, Fig 30 is due to the C-3 methyl group. The insertion of the iodo group is confirmed by 
the signal at δ 96.968 ppm. The presence of the carboxylic acid attached to the benzene ring is 
confirmed by the IR absorption band at νmax 1697 cm
-1
.  
   
 
Figure 29 
1
H NMR Spectrum of 2-iodo-3-methyl-5-methoxybenzoic acid 
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Figure 30 
13
C NMR Spectrum of 2-iodo-3-methyl-5-methoxybenzoic acid 
Finally, the oxidation of 4 with oxone in water produced the final product, Me-IBX in pure 
crystalline form. This oxidation results in the intramolecular cyclization of the compound 4 with 
the proposed mechanism illustrated in Scheme 16.   
 
Scheme 16 Oxidation of 2-iodo-3-methyl-5-methoxybenzoic acid by oxone 
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To confirm the formation of Me-IBX the 
1
H NMR with all the diagnostic signals corresponding 
of the protons present on the compound were observed viz., two singlet peaks at δ 6.81 and 6.92 
ppm attributable to the two aromatic protons H-4 and H-6 respectively, a 3-proton singlet at 3.67 
ppm which is due to the methoxy group and a 3-proton singlet at 2.44ppm accountable for the 
methyl group. To complement the 
1
H NMR results is the 
13
C NMR spectrum, Fig 47 illustrating 
a total of nine signals due to the nine carbons at different chemical shifts in the compound, 
emphasizing the distinguishable peak at 28.88 ppm for the C-7 methyl carbon, 55.45 ppm for the 
C-5 methoxy carbon, 88.02 ppm for C-7a and 169.48 ppm for the carbonyl group among others.  
Table 13 includes a summary of the results obtained for each compound synthesized.   
 
 
Figure 31 
13
C NMR Spectrum of Me-IBX 
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Table 13 Results of the synthesis of Me-IBX 
 Compound # 1H NMR (ppm) 13C NMR (ppm)  IR (cm-1) MS (m/z) [M+] mp (˚C)  
4  2.39 s (6H) 29.5   3275  247.06  130-135 
  6.59 s (2H) 97.0         
    114.2         
    143.2         
    155.1        
                
3   2.44 s (6H) 29.7    1586  269.1752 Liquid 
   3.76 s (3H) 55.2         
   6.66 s (2H) 97.0         
    112.8         
    142.7         
    159.1        
 
2  2.37 s (3H) 28.8    1697      138-140 
  3.72 s (3H)  55.4    1590      
  6.87 d (1H) 88.0    1566      
  7.04 d (1H) 111.6         
    117.1         
    141.2         
    143.4         
    158.8         
    169.4     
 
1  2.37 s (1H) 28.8    1694  322.9315   40-45 
  3.73 s (  55.5    1651      
  6.87  88.0    1584      
  7.04  111.7         
    117.2         
    141.1         
    143.5         
    158.6         
    169.5          
1H NMR solvents: CDCl3 or CD3OD 
IR solvents: CHCl2 or Nujol 
MS: ESI-MS [M+]      
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3.4. Retrosynthesis of target molecule (modified 1-hydroxy-1,2-benziodoxol-
3(1H)-one 1-oxide; mIBX 
As in the retrosynthesis discussed above, conversion of 7 to 6 via oxidation with oxone has been 
established as well as the conversion of 8 to 7 through the  Sandmeyer  reaction. Therefore 
synthesis of mIBX was envisaged to be possible by conversion of commercially available 2-
aminoterephthalic acid 8 to 2-iodoterephthalic acid 7 followed by  oxidation  with Oxone to the 
target molecule 6 Scheme 17.  
 
 
Scheme 17 The retrosynthesis of mIBX 
3.5. Preparation of target molecule 6 (modified Iodoxybenzoic acid) 
The two step synthesis of the oxidant mIBX (6) comprises of iodination of 2-aminoterephthalic 
acid to form 2-iodoterephthalic acid and oxone oxidation of the latter to the compound of interest 
Scheme 18. 
 
Scheme 18 Reagents and conditions: (i) NaNO2-HCl, KI, H2O, 18 h, 78 %; (ii) Oxone, H2O, 3 h, 56 %.  
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When amines are treated with nitrous acid (HONO), or more usually with a nitrile salt or an alkyl 
nitrite in acid solution, unstable diazonium salts are formed. The first step to take place is 
formation of the reactive species, nitrosonium ion (NO
+
) Scheme 19.  
 
 
Scheme 19 The formation of the nitrosonium ion
111
   
 
 
Scheme 20 Mechanism of formation of the diazonium salt 111 
 
Since R is an aryl group, the diazonium salt is relatively stable and thus results in the loss of 
nitrogen gas. However, the reaction is performed at low temperatures (0-5 ◦C), therefore 
increasing the stability of the salt making it stable enough to be reacted with nucleophiles such as 
I, Scheme 20
-
.111 
A key diagnostic feature in the 
1
H NMR spectrum of 2-iodoterephthalic acid Fig 32 was the 
absence of the amino group hydrogens present in the starting material and the presence of the 
three signals observed in the aromatic proton region due to the three aromatic protons on H-3, H-
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5 and H-6 at different chemical shifts. The two doublet signals observed at δ 7.58 and 7.81 ppm 
are attributable to the two protons H-6 and H-5 respectively while the singlet observed at δ 8.22 
ppm is due to the aromatic proton H-3. Further confirmation of the formation of the compound 
were  the signals obtained from 
13
C NMR spectroscopy complimenting the 
1
H NMR viz., the 
signal observed at δ 93.7 ppm, Fig 33 suggests that the C-N bond was converted to a C-I bond at 
C-2. The technique utilized for the purification of 2-iodoterephthalic acid was recrystallization, 
where the acid along with the impurities were dissolved in acetone. Hexane was slowly added to 
this mixture when 2-iodoterephthalic acid was observed to recrystallize out of the solution. 
 
 
Figure 32
1
H NMR Spectrum of 2-iodoterephthalic acid 
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Figure 33 
13
C NMR Spectrum of 2-iodoterephthalic acid 
The final step towards obtaining the compound of interest involves oxidation of 2-
iodoterephthalic acid using oxone which was achieved by treating 7 with oxone in the presence 
of water under reflux for 6 hours.  The mechanism followed by this reaction has been discussed 
in the synthesis of Me-IBX. The 
1
H NMR spectrum Fig 34 of this compound displays signals in 
the aromatic region. The singlet peak at δ 8.17 ppm, integrating for one proton, is attributable to 
H-7. The doublets at δ 7.91 and 8.02 ppm are due to H-4 and H-5 respectively. All of the signals 
present in the 13C spectrum, Fig 35 are accounted for and confirm the compound of interest. A 
big broad absorption band at 3420 cm
-1 
in the IR spectrum is due to the hydroxyl group on the 
compound. The carboxyl group is presented by the absorption band at 1637 cm
-1
. The molecular 
weight of mIBX is 323 g/mol. Therefore, the presence of the peak at 325 m/z calculated for 323 
g/mol indicates that the product has been formed.  
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Figure 34 
1
H NMR Spectrum of mIBX 
 
 
Figure 35 
13
C NMR Spectrum of mIBX 
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Table 14 Results of the synthesis of mIBX 
Compound # 
1
H NMR (ppm) 
13
C (ppm)  IR (cm
-1
) MS (m/z) mp (˚C)________ 
7  7.58  93.7  1694  292.9301 Above 300  
  7.81  128.8  1555       
  8.22  129.8         
    133.6         
    140.6         
    141.0         
    165.2         
    167.9 
  
6  6.67  121.1  3420  325.2511 Above 300  
  6.72  127.3  1637       
  7.15  131.362         
    131.431         
    135.010         
    136.375         
    165.967         
    167.120 
___________________________________________________________________________ 
1
H NMR solvents: dimethyl sulfuxide-d6 
IR solvents: CHCl2 or Nujol 
MS: ESI-MS [M
+
] 
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CHAPTER 4 
RESULTS AND DISCUSSION 
4.1 Activation strategy  
As mentioned before, the conjugation strategy of the polysaccharide to the protein involves the 
derivatization of both the starting materials prior to conjugation. This chapter focuses on the 
actual reactions performed in modifying the protein and polysaccharide, subsequently their 
conjugation towards the development of a conjugate vaccine.  
4.1.2 Activation of BSA 
Albumins, being a family of globular proteins are unglycosylated, water soluble proteins 
commonly found in blood plasma. They are composed of a number of amino acids.
33
 Table 15 
illustrates the total amino acid composition in BSA.  
Table 15 Amino acid composition of BSA
33
 
Ala 48 Cys 35 Asp 41 Glu 58 
Phe 30 Gly 17 His 16 Ile 15 
Lys 60 Leu 65 Met 5 Asn 14 
Pro 28 Gln 21 Arg 26 Ser 32 
Thr 34 Val 38 Trp 3 Tyr 21 
   
At TBI, the Lee-Frasch method is employed for derivatisation of the protein carrier. This method 
targets amino acids containing carboxylic acid side chains for activation. Thus, if one considers 
BSA as the model protein carrier, Aspartic acid and Glutamic acid fits the bill. Therefore BSA 
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contains 99 carboxyl groups from (Asp and Glu, highlighted in the above table) and thus will be 
targeted by the hydrazides present in ADH during protein activation.
33
  
 
 
Scheme 21 Activation of protein mechanism 
 
EDC reacts with a carboxyl group on the protein Scheme 21, forming an amine-reactive O-
acylisourea intermediate. This highly activated form of the carboxylic acid intermediate then 
reacts with the ADH molecule, yielding a conjugate of the two molecules joined by a stable 
amide bond.  
Protein activation 
Bovine Serum albumin was derivatized by dissolving 500.4 mg in 0.2 M NaCl (20 ml) at a pH of 
4.4. To this mixture, ADH (1.72 g; 3.45 mg/mg protein) was added and the solution was stirred 
to dissolve the contents. With the addition of EDC (51.2 mg; 0.1 mg/mg protein) to the solution, 
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the pH rose to 7.13 and was adjusted down to 4.75 and kept constant for 90 mins with 0.1 M 
HCl. The reaction was then quenched with 3.5 M NaOH and the pH maintained at 9.5.  
The solution was dialfitered against 3 L of 3 mM Na2CO3/30 mM NaCl at a pH of 10.5 on a lab 
scale. The purpose of diafiltration is to remove excess starting reagents. In order to track this, a 
process test was established to follow the removal of starting reagents eg. ADH, in the clean-up 
process. This test incorporates 1% TNBS (100 µl) + 0.1 N Sodium borate (100 µl) of which 2 
drops  were introduced to the test solution and if the color of the mixture turned dark orange, that 
suggested that there was still some ADH in the mixture. However, if the color remained yellow, 
this indicates complete removal ADH in the mixture. The total volume of the buffer used was 
1650 ml and after the diafiltration, the solution was concentrated down to 50ml. The extent of 
derivatization with ADH was determined using the TNBS assay with ADH as a standard.  
Upon completion of BSA activation, a coomassie assay was done on the derivatized protein to 
confirm the concentration of protein in the sample. A further analysis was done by HPLC and the 
TNBS assay to assess whether derivatization had indeed occurred, and the concentration of 
hydrazides present as well as the degree of substitution of the hydrazides on the molecule (Table 
16).  
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Figure 36 BSA-AH-UV signal shodex 805-804 in series; injection volume 50µl; flow rate 1ml/min; 
15/06/2010 
Discussion 
Since SEC is governed around larger molecules eluting earlier from the column with smaller 
molecules being retained for longer times. A peak at 18.036 min is observed which corresponds 
to neat BSA, Fig 36. This is known as neat BSA has been analysed on the HPLC in previous 
experiments, therefore its elution time is well known. A new peak with a retention time of 
18.776 min corresponds to the activated BSA (BSA-AH). The activated BSA is observed to have 
been size reduced upon activation; hence the elution time being later than that of inactivated 
BSA. However, at TBI experiments have been performed to try and find out why activated BSA 
takes a longer time to elute from the column. The conclusion reached was that the hydrazides 
that have reacted with the hydroxyl groups tend to interact more strongly with the column 
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contents resulting in a longer elution time. The separation of the two peaks confirms that 
activation has occurred on BSA. 
 
Table 16 Results obtained for BSA activation by ADH 
Protein Of Interest Bovine Serum Albumin (BSA) 
Reaction completion time 90 min 
Final dialysis buffer 3 mM Na2CO3/30 mM NaCl 
Final concentration (mg/ml) 15.36 mg/ml 
Hydrazide concentration 4.72 mM 
% carboxylic substitution 20.6 
 
4.2 PRP microfluidization 
4.2.1 Size reduction of PRP in water 
PRP (313 mg, 10.44 mg/ml) solubilised in water at 10.44 mg/ml was loaded into the 
microfluidizer sample glass reservoir and then exposed to 20 000 psi for a maximum of 4 passes. 
After each pass through the microfluidizer, a 1 ml aliquot was taken for analysis and the rest 
returned back to the glass reservoir. The return coil was cooled with ice water to avoid heating 
up of sample. After size reduction, the machine was cleaned by adding water (250 ml) to rinse 
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off the PS stuck on the walls of the processor, followed by 0.2 M NaOH (500 ml) and finally 
water (500 ml). The samples were then diluted to 2 mg/ml with purified water for analysis on the 
HPLC.  
PRP Microfuidisation, RID, shodex 805-804 50ul injections 
29/06/2010
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Figure 37 P49 in water microfluidization (20 000 psi; 4 cycles); shodex 805-804 in series; injection 
volume 50 µl; flow rate 1 ml/min, 29/06/2010 
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Table 17 Change in molecular size with increasing number of passes of PRP in water through the 
microfluidizer 
PRP 
in 
water       
Starting 
molecular 
weight 
(kDa) 
Pressure 
(psi) 
 
Retention 
time 
(min) 
Number 
of 
passes 
Final 
molecular 
weight as 
determined by 
Pullulan 
standards 
(kDa) 
% Area 
under 
curve 
(relative 
to the 
main 
peak) 
Polydispersity 
(Peak width at ½ 
max height/max 
peak height) 
PRP 618  20000  
13.59 0 618 100 0.96 
13.85 1 507 99.7 0.94 
14.51 2 318 95.29 0.85 
14.66 3 287 88.89 0.85 
14.77 4 265 86.00 0.72 
  
Pullulan standards were used to estimate the molecular weight of the polymer chain. The log of 
the molecular weight (log Mr) of a set of pullulan standards was determined as well as the 
elution time obtained from the HPLC (Table 18). A calibration curve was then compiled by 
drawing a graph of the log of the molecular weight against the elution time giving a straight line 
with a negative slope Graph 7. From such a graph, if the elution time of a sample under analysis 
is obtained, the molecular weight may be determined from the standard curve.   
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Table 18 Standard curve and sample calculations with reference to pullulan standards 
 
log (Mr) (kDa) vs Ve
y = -0.0054x3 + 0.2522x2 - 4.1805x + 26.646
R2 = 0.999
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Graph 7. Pullulan standards calibration curve 
Discussion 
We used HPLC fitted with shodex (SEC) columns which separates molecules on the basis of 
size. It is primarily used for the analysis of large molecules such as proteins and polymers. SEC 
works by trapping the smaller molecules in the pores of the particles making up the shodex 
matrix. The larger molecules simply pass by the pores as they are too large to enter the pores. 
Standard curve and Sample Calculations:
Standard Mw (from CoA) kDa log (Mr) Ve (=Te) min Kd Sample Sample Ve Sample Kd Log Mr Mr (Kda)
P-800 788 2.897 13.301 0.182 PRP neat 13.59 0.206 2.792 618.803
P-200 212 2.326 15.163 0.336 PRP -2 cycle 15.82 0.390 2.138 137.561
P-100 112 2.049 16.114 0.415 PRP-3 cycles 15.29 0.347 2.281 191.163
P-50 47.3 1.675 17.223 0.507 PRP-4cycles 15.52 0.366 2.218 165.343
P-20 22.8 1.358 18.175 0.586
P-10 11.8 1.072 18.842 0.642
P-11 5.9 0.771 19.44 0.691
Equation: log Mr =K3Ve^3 + K2Ve^2 + K1Ve + Ko
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Larger molecules therefore flow through the column quicker than smaller molecules, that is, the 
smaller the molecule, the longer the retention time. From the chromatogram in Fig 37, one can 
definitely note a shift in the peak amplitudes as the number of cycles increases. This means that 
the size of the polymer is size reduced as it is passed through the microfluidizer.  The sizes of the 
polysaccharide as calculated by using the Pullulan standards seem to confirm the decrease in the 
molecular weight after every microfluidization cycle. The overall decrease went from 618 kDa to 
265 kDa, Fig 37.  
The area under the curve also appears to be decreasing with increasing the number of passes 
through the microfluidizer. This means that as the sample is passed through the machine, it 
experiences a slight loss in its molecular weight. As for the polydispersity of the samples, taking 
ratios of peak width at half maximum peak height over maximum peak height demonstrates that 
the polydispersity is decreasing with increasing numbers of cycles through the machine but the 
decrease is not significant.  
4.2.2 Size reduction of PRP in 0.2 M NaCl 
PRP (313 mg, 10.44 mg/m) solubilised in water was dialysed using a lab scale TFF system, fitted 
with 10 k polyethersulfone membranes. This device serves to reconstitute PRP into NaCl. 900 ml 
of 0.2 M NaCl was used to fully exchange the buffer from water to NaCl 0.2 M. This was then 
loaded in the microfluidizer processor sample glass reservoir. The sample was then exposed to 
20 000 psi for 4 passes. After each pass through the microfluidics, a 1ml aliquot was taken for 
analysis and the rest returned back to the glass reservoir. The return coil was cooled with ice 
water to avoid heating up of sample. After size reduction, cleaning followed as in 2.2.1. The 
samples were then diluted to 2mg/ml with purified water for analysis on the HPLC. The HPLC 
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results proved that as the polysaccharide was passed though the microfluidizer, it was size 
reduced. This is deduced from the retention time increasing as the number of passes through the 
microfluizider increases Fig 38 resulting in the final molecular weight of the polysaccharide as 
determined by pullulan standards decreasing table 17. 
PRP in NaCl Microfuidisation, RID, shodex 805-804 50ul injections 
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Figure 38 P49 in 0.2 M NaCl microfluidization (20000 psi; 4 cycles); shodex 805-804 in series; injection 
volume 50 µl; flow rate 1 ml/min 
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Table 19 Change in molecular size with increasing number of passes of PRP in 0.2 M NaCl through the 
microfluidizer 
PS 
Starting 
molecular 
weight 
kDa 
Pressure 
psi 
 
Retention 
time 
(min) 
Number 
of 
passes 
Final molecular 
weight as 
determined by 
Pullulan standards 
(kDa) 
% 
Area 
under 
curve 
(relative 
to the 
main 
peak) 
Polydispersity 
(Peak width at ½ 
max height/max 
peak height) 
PRP 
in 
0.2M 
NaCl 
618 20000 
15.29 2 191 100.00 0.87 
15.52 3 165 89.03 0.75 
15.82 4 137 79.84 0.95 
 
4.2.3 Size reduction of PRP dissolved in 10 mM PBS 
PRP (313 mg, 10.44 mg/ml) solubilised in water was dialysed using a lab scale TFF system, 
fitted with 10 k polyethersulfone membranes. 900 ml of 10 mM PBS was used to fully exchange 
the water. This was then loaded in the microfluidizer processor sample glass reservoir. The 
sample was then exposed to 20 000 psi for 4 passes. After each pass through the microfluidics, a 
1ml aliquot was taken for analysis and the rest returned back to the glass reservoir. The return 
coil was cooled with ice water to avoid heating up of sample. After size reduction, cleaning 
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followed as in the first two reactions. The samples were then diluted to 2mg/ml with purified 
water for analysis 
PRP in PBS Microfuidisation, RID, shodex 805-804 50ul injections 
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Figure 39 P49 in 10 mM PBS microfluidization (20 000 psi; 4 cycles); shodex 805-804 in series; injection 
volume 50 µl; flow rate 1 ml/min 
Table 20 Change in molecular size with increasing number of passes of PRP in 10 mM PBS through the 
microfluidize 
PS 
Starting 
molecular 
weight 
kDa 
Pressure 
psi 
 
Retention 
time 
(min) 
Number 
of 
passes 
Final 
molecular 
weight as 
determined 
by Pullulan 
standards 
(kDa) 
% Area 
under 
curve 
(relative to the 
main peak) 
Polydispersity 
(Peak width at ½ 
max height/max 
peak height) 
PRP 
in 
PBS 
618 20000 
14.99 2 231 100.00 0.83 
15.19 3 204 96.7 0.89 
15.17 4 206 86.54 0.84 
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Discussion 
PRP was dissolved diafiltered and microfluidised using three different buffers. Other parameters 
viz., pressure and temperature were kept constant. This was done to evaluate the effect different 
buffers would have on the final sizes of the samples after the microfluidization process. The 
results obtained illustrated that buffers do in fact have effects on size reduction and therefore 
impact on the final results one gets. In this experiment, of the three buffers used, 0.2M NaCl 
demonstrated the best buffer action in the size reduction of PRP. Without any significant change 
in the polydispersity of the sample, 0.2M NaCl gave the largest decrease in its molecular size. 
The initial molecular size of the polymer after microfluidization was 618 Kda and the resultant 
molecular size was 137 kDa (Figure 38 and table 19). The area under the curve appeared to 
experience a slight decrease after each pass through the microfluidiser. This is because the 
sample experience loss in molecular weight due to microfluidization. However, since the 
polydispersity is more or less the same, the integrity of the sample was not distorted. 
The results obtained for 10 mM PBS were very similar to those obtained for 0.2 M NaCl. The 
polydispersity of the sample was almost constant. The area under the curve demonstrated a 
decrease after every pass through the microfluidiser. Compared to water as the buffer, 10 mM 
PBS gave better results in the reduction of the molecular size. The overall decrease in was from 
618 kDa down to 206 kDa (Figure 39 and table 20).    
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4.3 Activation of PRP  
4.3.1 Activation of PRP using DMP 
To a solution of PRP in water (50 mg, 10.44 mg/ml) in a mixture of an equivalent amount of 
acetonitrile was added DMP (61 mg; 424.15 g/mol). The homogenous solution was left stirring 
for 5 hours at room temperature. After 5 hrs, a precipitate was observed and was ultra-filtered. .  
The solution was dialysed in 2L of 0.2 M NaCl with the use of 10 000 MWC dialysis cassettes. 
The conjugate was then diluted down to 2 mg/ml in preparation for analysis on the HPLC.  This 
was to assess the formation of the conjugate. Fig. 40 below shows the results obtained from the 
HPLC chromatograms. 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 PRP-DMP activation; RID signal shodex; 805-804 injection volume 50 µl; flow rate 1ml/m  
in; 29/09/2010 
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4.3.2 Activation of PRP using IBX 
To a solution of PRP in water (50 mg, 10.44 mg/ml) in a mixture of an equivalent amount of 
acetonitrile was added DMP (88 mg; 280. 02 g/mol). The homogenous solution was left stirring 
for 5 hours at room temperature. After 5 hrs, a precipitate was observed and ultra-filtered. The 
solution was then dialysed in 2L of 0.2 M NaCl with the use of 10 000 MWC dialysis cassettes. 
The conjugate was then diluted down to 2 mg/ml in preparation to be used on the HPLC for 
analysis. This was to check whether the conjugate had formed or not. Fig. 41 below shows the 
results obtain from the HPLC chromatograms.   
 
 
 
 
 
 
 
 
 
 
Figure 41 PRP-IBX activation; RID signal shodex; 805-804 injection volume 50 µl; flow rate 1ml/min; 
29/09/2010 
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the PRP earlier, in the experiment, it gave a final size of PRP with an elution time of 14.77 min. 
Therefore, the elution time for neat PRP is expected to be more or less 14.77 min. A new peak 
eluting at 18.806 min, which is believed to be due to DMP oxidised PRP is also observed. Since 
the principle of SEC is governed around larger molecules eluting first, oxidised PRP using DMP 
appeared to have been size reduced by the reagent.  
Fig 41 illustrates the similar IBX reaction which shows similar results to the DMP reaction. We 
notice a peak with a retention time of 14.890 min attributable to neat PRP. A new peak, eluting 
at 18.720 min is also observed. This peak is due to IBX oxidised PRP. As in the DMP reaction, 
the molecular size of PRP has been reduced. These results were unexpected because according to 
the proposed mechanism for mIBX presented in Scheme 9, the oxidant is expected to convert the 
primary hydroxyl groups to aldehydes instead of size reducing the polysaccharide, however such 
results were interesting. The conjugation experiment was continued nevertheless to see what 
would happen when the new PRP was coupled to BSA_AH.  
4.3.3 Coupling of PRP to BSA  
Upon completion of PRP oxidation, the resultant product was coupled to BSA_AH. This was 
achieved by adding PRP (50 mg; 8.13 mg/ml) to BSA (25 mg; 13.391 mg/ml) in a Schott bottle. 
The reaction was left overnight and the following day, the solution was diluted to 2 mg/ml in 
preparation for the analysis on the HPLC. The results obtained on the HPLC are represented in 
Figs 42 - 45.   
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Figure 42 BSA_AH-PRP_IBX conj-RID signal: Shodex 805/804 in series: 50 µl; flow rate 1 ml/min: 
17/09/2010  
 
 
 
 
 
 
 
 
 
 
Figure 43 BSA_AH-PRP_IBX conj-UV 280 signal: Shodex 805/804 in series: 50 µl; flow rate 1 
ml/min: 17/09/2010 
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Figure 44 BSA_AH-PRP_DMP conj-RID signal: Shodex 805/804 in series: 50 µl; flow rate 1 ml/min: 
17/09/2010 
 
 
 
 
 
 
 
 
 
 
 
Figure 45 BSA_AH-PRP_DMP conj-UV 280 signal: Shodex 805/804 in series: 50 µl; flow rate 1 
ml/min: 17/09/2010 
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Discussion 
Fig. 42 is the RID signal of the IBX formed conjugate showing the elution time of the supposed 
conjugate and unconjugated PRP. The peak observed at 19.166 min is due to unconjugated PRP. 
The new peak eluting at 13.339 min suggests that the conjugate might not have been formed.  
This peak appears to be attributable to free polysaccharide. To confirm this, the UV spectra were 
performed (Fig 43) which illustrates the UV signals showing the elution of the supposed 
conjugate and free protein. The unconjugated protein is represented by the peak eluting at 18.036 
min followed by the new conjugate peaks at 19.319 min and 21.417 min. Almost similar results 
were obtained using DMP as oxidant (Figs 44 and 45). It was decided to test these new conjugate 
peaks with a full battery of assays and the results are tabulated in Table 21 below. 
Table 21 Summary of the PRP concentration throughout the process 
PRP-IBX PRP-DMP 
PRP (50 mg) + BSA (25 mg) + ACN (4.79 ml) + 
IBX (88 mg; 280.15 g/ml) 
Total sugar (Ribose assay) 
PRP = 35.88 mg 
Free sugar (DOC assay) 
PRP = 0.5 mg 
Sugar in conjugate (Ribose – DOC) 
PRP = 35.38 
% Yield of PRP in conjugate 
70.76 % 
PRP (50 mg) + BSA (25 mg) + ACN (4.79 ml) + 
DMP (61 mg; 424.15 g/ml) 
Total sugar (Ribose assay) 
PRP = 36.48 mg 
Free sugar (DOC assay) 
PRP = 0.5 mg 
Sugar in conjugate (Ribose – DOC) 
PRP = 35.98 mg 
% Yield of PRP in conjugate 
71.96 % 
 
 
 
 
  
134 
The resulting mixtures obtained from IBX and DMP oxidised PRP conjugates to BSA, were 
investigated by performing a number of different assays. From the assays performed on these 
conjugates (Table 21), the results show that there is not a lot of free sugar in the product, 70% of 
the sugar in the product is conjugated to the protein. These results differ from those obtained 
from the HPLC. This was confusing, since from the HPLC chromatograms, no definitive peak 
corresponding to a conjugate was observed. Instead, the observed was a peak appeared to 
correspond to free PRP. It was suggested that the reason for these results was due to the fact that 
the PRP used was in a water solution. The presence of large amounts of water when used as a 
solvent or co solvent, is unfavourable to the outcome of the oxidation reactions using these 
reagents.  
4.3.4.1 Activation of PRP using mIBX (1:1 PRP:mIBX) 
To a solution of PRP (53.284 mg; 0.154 mmol) in DMSO (5 ml)(3:2 v/v) was added mIBX (50 
mg; 0.154 mmol) in a 1:1 ratio. The reaction mixture was heated until all the mIBX had 
dissolved. As soon as all the mIBX had dissolved, the temperature was decreased to room 
temperature. The reaction was left stirring for 3 hours. Subsequently, the product mixture was 
dialysed overnight in a solution of 0.2 M NaCl. The buffer was changed to purified water the 
following morning and the product mixture was left in dialysis for 24 hours. The dialysis was 
performed using 20 000 MWC dialysis cassettes. HPLC and the BCA aldehyde assay were used 
to analyse the product.  
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Figure 46 PRP-mIBX activation; RID signal shodex; 805-804 injection volume 50 µl; flow rate 1ml/min;  
 
4.3.4.2 Activation of PRP using mIBX (1:2 PRP:mIBX ratio) 
To a solution of PRP (26.6 mg; 0.077 mmol) in DMSO (5 ml)(3:2 v/v) was added mIBX (50 mg; 
0.154 mmol) in a 1:2 ratio. The reaction mixture was heated until all the mIBX had dissolved. As 
soon as all the mIBX had dissolved, the temperature was decreased to room temperature. The 
reaction was left stirring for 3 hours. Subsequently, the product mixture was dialysed overnight 
in a solution of 0.2 M NaCl. The buffer was changed to purified water the following morning 
and the product mixture was left in dialysis for 24 hours. The dialysis was performed using 20 
000 MWC dialysis cassettes. HPLC and the BCA aldehyde assay were used to analyse the 
product.  
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Figure 47 PRP-mIBX activation; RID signal shodex; 805-804 injection volume 50 µl; flow rate 1ml/min;  
 
 
 
4.3.4.3 Activation of 19F using mIBX  
To a solution of serotype 19F (48.55 mg; 0.077 mmol) in a H2O;DMSO (3;2 v/v) solution was 
added mIBX (25 mg; 0.077mmol). The solution was heated until all the mIBX had dissolved 
after which, the temperature was allowed to reach room temperature.  The resultant mixture was 
left stirring for 3 hours. This was then dialysed with the solution of 0.2 M NaCl overnight using 
3500 MWCO cassettes. The buffer was exchanged by purified water and left for 24 hours.     
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Figure 48 19F-mIBX activation; RID signal shodex; 805-804 injection volume 50 µl; flow rate 1ml/min;  
 
Apart from the polysaccharide being size reduced upon oxidation (Figs 68, 69 and 71), the 
results obtained from the BCA aldehyde (table 22) assay analysis also illustrate that there was 
some degree of oxidation of the polysaccharide by mIBX. When a ratio of 1:1 PRP: mIBX was 
tested with a reaction time of 3 hours, an aldehyde concentration of 0.06 mM was obtained. It 
was decided to change the ratio and time, optimising the parameters at which the experiment was 
performed to 1:2 ratio of PRP: mIBX and lengthen the reaction time to 6 hours in order to 
increase the resultant aldehyde concentration. However, the BCA aldehyde revealed a decrease 
in the aldehyde concentration to 0.04 mM (table 22) and the HPLC chromatogram results 
revealed a size reduction of about 5 units.  
It was concluded that because PRP contains a 5-membered ring and IBX oxidises through a 
radical methodology and is formed upon the α-H abstraction from the primary alcohol by the 
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oxidant, is unstable due to the lack of any form of delocalisation and thus the radical, in trying to 
stabilise itself, moves into the ring, opening it up and leading to size reduction.  
It was decided that the next step would be to test the oxidant on a 6-membered ring (Pn 6B) and 
investigate its behaviour. However, because there was access to Pn 19F, which possesses similar 
features to Pn 6B, the experiment was performed on Pn 19F. The ratio used was a 1:1 Pn 
19F:mIBX and the reaction time was 3 hours. These parameters were decided upon based on the 
results obtained from the PRP experiments that illustrated that the more IBX used and the longer 
the reaction time, the more the PS is size reduced and the less aldehyde concentration is 
obtained. The results for Pn 19F showed a higher aldehyde concentration of 0.09 mM and a size 
reduction factor of about 2-units. These results were in close agreement with the conclusion 
made from the results obtained with PRP.  
 
 
Table 22 The results obtained for the polysaccharide oxidation with mIBX 
Polysaccharide PS/mIBX ratio Time (hrs) Aldehyde concentration (mM) 
PRP 1:1 3 0.06 
PRP 1:2 6 0.04 
19F 1:1 3 0.09 
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CONCLUSION 
In the trial to synthesize alternative oxidants to the well known oxidants mentioned in the 
above chapters, derivatives of IBX to be exact, in view of developing novel hypervalent 
conjugation strategies towards a conjugate vaccine, two oxidants were successfully 
synthesized (Me-IBX and mIBX). Analysis thereof, with NMR, IR and MS confirmed that 
the compounds synthesized are indeed the desired compounds. However, the compounds 
also proved to be soluble in the organic solvent DMSO and not in water.  
The attempt to develop a size reduction strategy towards size reducing long polysaccharide 
chains in preparation for derivatization was successfully accomplished using a 
microfluidiser. 
The oxidants were tested on polysaccharide oxidation in converting primary alcohols to 
aldehydes and were found to produce aldehydes but only in small concentrations. The 
aldehyde concentration obtained was not enough to test whether the polysaccharide could be 
conjugated to protein, therefore that aspect couldn’t be met. However, this area leaves room 
to be explored in future research, as reaction parameters such as time, ratio and temperature 
are factors that need to be investigated in maximising aldehyde concentration in an oxidised 
polysaccharide. Should a moderate aldehyde concentration be achieved, then conjugation of 
polysaccharide to protein, towards a conjugate vaccine would be tested.  
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CHAPTER 5 
EXPERIMENTAL 
5.1 General  
The solvents used were purified according to standard procedures before being stored in tightly 
sealed solvent storage bottles. The 
1
H and 
13
C NMR measurements were recorded on a Varian 
XR200 MHz spectrometer. The 
1
H and 
13
C chemical shifts were referenced internally using the 
residual CDCl3 (99.9%) and reported relative to the internal standard tetramethylsilane (TMS). 
Infrared spectroscopic measurements in the range between 4000 and 450 cm
-1 
were recorded on 
Perkin-Elmer spectrum-100 Series FT-IR spectrophotometer.  
 
5.2 The synthesis of Modified O-Methyl substituted-1-hydroxy-1,2-benziodoxol-
3(1H)-one 1-oxide  
 5.2.1 4-iodo-3,5-dimethylphenol (2) 
 
Figure 49 4-iodo-3,5-dimethylphenol 
To a solution of potassium iodate (KIO3; 5.64 g, 26.2 mmol) and potassium iodide (KI; 8.2 g, 
49.2 mmol) in water (82 ml) was added a solution of 3,5-dimethylphenol (10 g, 81.9 mmol) in 
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MeOH (150 ml) and hydrochloric acid, HCl (66 ml). The addition was done at 0˚C and the 
resultant mixture was stirred at this temperature for 2 hrs during which time, a white solid 
precipitate was formed. The precipitate was the filtered off, washed with water and dried to 
obtain 4-iodo-3,5-dimethylphenol (12.26 g, 49.42 mmol). Yield: 60.3%; mp: 130-135 ˚C; 1H 
NMR (CDCl3, 200 MHz) δ 2.39 (s, 6H), 6.59 (s, 2H); 
13
C NMR (CDCl3, 200 MHz) δ 29.6, 97.0, 
114.2, 143.2, 155.1; IR (CH2Cl2) cm
-1 
3275, 1580, Mass spectrum, m/z 247.1668 (M
+
), 
calculated for C8H9IO, 248.06 (M
+
) 
 
5.2.2 4-iodo-3,5-dimethylanisole (3) 
 
Figure 50 4-iodo-3,5-dimethylanisole 
To a solution of 4-iodo-3,5-dimethylphenol (12.14 g; 48.9 mmol) in dimethylsufoxide, (DMSO) 
(100 ml) was added potassium hydroxide, (KOH) (10.95 g; 195.6 mmol) and the reaction was 
performed at room temperature. The resultant mixture was stirred for 10 min after which methyl 
iodide (MeI) (6.07 ml) was introduced drop wise with further stirring for 2 hours while 
monitoring with TLC (20% EtOAc/Hex) . The reaction was quenched with water and the product 
was extracted with petroleum ether (3 × volumes; 100 ml). The organic layer was washed with 
brine dried with magnesium sulphate, (MgSO4) and the solvent was removed using a rotor 
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evaporator to obtain the product 4-iodo-3,5-dimethylanisole (12.16 g; 46.4 mmol).as a liquid. 
Yield: 94.8%. 
1
H NMR (CDCl3, 200 MHz) δ 2.44 (s, 6H) 3.76 (s, 3H), 6.66 (s, 2H); 
13
C NMR 
(CDCl3, 200 MHz) δ 29.7, 55.2, 97.0, 112.8, 142.7, 159.1; IR cm
-1
 1586, Mass spectrum, m/z 
269.1752 (M
+
), calculated for C9H11IO, 262.06 (M
+
)  
5.2.3 2-iodo-3-methyl-5-methoxybenzoic acid (4) 
 
Figure 51 2-iodo-3-methyl-5-methoxybenzoic acid (4)  
A solution of potassium permanganate (KMnO4) (14.4 g; 93.5 mmol) in water (170 ml) was 
added to a solution of 4-iodo-3,5-dimethylanisole (3.5 g; 13.4 mmol) in pyridine (20 ml) at 
100
ᵒ
C over a period of 45 min. The mixture was cooled, filtered and washed off with a sodium 
hydroxide, NaOH solution 10%. The filtrate obtained was acidified with HCl and the product 
extracted with ethyl acetate EtOAc (4× volumes, 100 ml). The organic layer was subjected to 
silica gel to separate the two products formed from this reaction: 2-iodo-3-methyl-5-
methoxybenzoic acid with 60% EtOAc/Hexane (1.24 g; 4.24 mmol) and 2-iodo-5-
methoxyisophthalic acid. Yield: 15.87%. mp: 138-140 ˚C; 1H (DMSO-d6, 200MHz) δ 2.37 (s, 
3H), 3.73 (s, 3H), 6.87 (d, 1H, J = 3 Hz), 7.04 (d, 1H, J = 2.8 Hz); 
13
C NMR (CDCl3, 200 MHz) 
δ 28.8, 55.4, 88.0, 111.6, 117.1, 141.2, 143.4, 158.8, 169.4; IR (CH2Cl2) cm
-1
 1697, 1590, 1566     
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5.2.4 Modified Me-IBX (6) 
 
Figure 52 Me-IBX 
To a solution of 2-iodo-3-methyl-5-methoxybenzoic acid (1.24 g; 4.24 mmol) in water (15 ml) 
was added oxone (3.91 g; 6.37 mmol). The resultant mixture was stirred at 65-70 ˚C overnight. 
The solid precipitate was filtered and dried to obtain the hypervalent iodine compound, a cream 
colored solid (0.45 g; 1.38 mmol). Yield: 32.76%. Mp: above 300˚C; 1H NMR (DMSO-d6, 200 
MHz) δ 2.32 (s, 3H), 3.67 (s, 3H), 6.81 (s, 1H), 6.92 (s, 1H); 13C NMR (DMSO-d6, 200 MHz) δ 
28.8, 55.5, 88.0, 111.7, 117.2, 141.1, 143.5, 158.9, 169.5; IR (Nujol) cm
-1
 1694, 1651, 1584, 
mass spec m/z, 322.9315(M
+
), calculated for C9H9IO5, 323.9 (M
+
) 
5.3 The Synthesis of modified-Iodoxybenzoic acid 
5.3.1 2-iodoterephthalic acid 
 
Figure 53 2-iodoterephthalic acid 
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A solution of NaNO2 (2.85g; 41.3mmol) in water (50ml) was introduced to a solution of 2-
aminoterephthalic acid (3.0g; 16.6mmol) in HCl; THF, 1:1 v/v (50ml) dropwise over a period of 
30 min at 0-5C, during which time the solution became clear. After being stirred for an 
additional 30 min at the same tempertaure, the diazonium salt was poured into a solution of KI 
(16.5g; 9.94mmol) in water (150ml) and the resultant mixture was left stirring for 18hrs at room 
temperature. After the 18 hrs, sodium bisulphite was added to the mixture for decolorization of 
the sloution. The precipitated was filtered off and titurated 1:1 (v/v) CH2Cl2-H2O to give the 3-
iodoterephtalic (3.78g, 12.945mmol) acid as a white solid. Yield; 77.98% mp: above 300 ˚C; 1H 
NMR (DMSO-d6, 200 MHz) δ 7.58 (d, 1H, J = 6.2 Hz), 7.81 (d, 1H, J = 6.2 Hz), 8.22 (s, 1H); 
13
C (DMSO-d6, 200 MHz) δ 93.7, 128.8, 129.8, 133.6, 140.6, 141.0, 165.2, 167.9; IR (Nujol) cm
-
1 
1694, 1555, mass spec m/z, 292.9301 (M
+
), calculated for C8H5IO4, 292.03 (M
+
) 
5.3.2 The preparation of mIBX 
 
Figure 54 mIBX 
A mixture of 2-iodoterephthalic acid (3.78g, 12.94mmol) and oxone (23.87g, 38.8mmol) in 
water (200ml) was maintained at reflux for 3 hrs during which time the solution became clear. 
The hot solution was poured into a bigger beaker  and allowed to cool at room temperature. The 
precipitated cream coloured solid was filtered and dried to yeild the disired product (2.3g, 
7.1mmol). Yield: 54.7%, mp: above 300 ˚C, 1H NMR (DMSO-d6, 200 MHz) δ 7.91 (d, 1H, J = 8 
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Hz), 8.02 (d, 1H, J = 8.2 Hz), 8.17 (s, 1H); 
13
C NMR (DMSO-d6, 200 MHz) δ 121.1, 127.3, 
131.4, 131.4, 135.0, 136.4, 166.0, 167.1; IR (Nujol) cm
-1 
3420, 1637,  mass spec, m/z 325.5211 
(M
+
), calculated for C8H5IO6, 323.9 (M
+
) 
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APPENDIX 
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IR spectrum of 4-iodo-3,5-dimethylphenol 
 
 
1
H NMR spectrum of 4-iodo-3,5-dimethylanisole 
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13
C NMR spectrum of 4-iodo-3,5-dimethylanisole 
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IR spectrum of 4-iodo-3,5-dimethylanisole 
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IR spectrum of 2-iodo-3-methy-5-methoxybenzoic acid 
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IR spectrum of Modified Me-IBX 
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IR Spectrum 2-iodoterephthalic acid 
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IR Spectrum of mIBX 
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